<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0505210719
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1999
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RISPERDAL 1MG-ML SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RISPERIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        170.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN PHARMACEUTICA N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Risperdal belongs to a group of medicines called &lsquo;antipsychotics&rsquo;.</p><p>Risperdal is used to treat the following:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Schizophrenia, where you may see, hear or feel things that are not there, believe things that are not true or feel unusually suspicious, or confused</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Mania, where you may feel very excited, elated, agitated, enthusiastic or hyperactive. Mania occurs in an illness called &ldquo;bipolar disorder&rdquo;</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Short‑term treatment (up to 6&nbsp;weeks) of long‑term aggression in people with Alzheimer&rsquo;s dementia, who harm themselves or others. Alternative (non‑drug) treatments should have been used previously</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Short‑term treatment (up to 6&nbsp;weeks) of long‑term aggression in intellectually disabled children (at least 5&nbsp;years of age) and adolescents with conduct disorder.</p><p>&nbsp;</p><p>Risperdal can help alleviate the symptoms of your disease and stop your symptoms from coming back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Risperdal</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>If you are allergic to risperidone, sunset yellow or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>If you are not sure if the above applies to you, talk to your doctor or pharmacist before using Risperdal.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Risperdal if:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have a heart problem. Examples include an irregular heart rhythm or if you are prone to low blood pressure or if you are using medicines for your blood pressure. Risperdal may cause low blood pressure. Your dose may need to be adjusted</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You know of any factors which would favour you having a stroke, such as high blood pressure, cardiovascular disorder or blood vessel problems in the brain</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have ever experienced involuntary movements of the tongue, mouth and face</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have ever had a condition whose symptoms include high temperature, muscle stiffness, sweating or a lowered level of consciousness (also known as Neuroleptic Malignant Syndrome)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have Parkinson&rsquo;s disease or dementia</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You are diabetic</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have epilepsy</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You are a man and you have ever had a prolonged or painful erection</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have problems controlling your body temperature or overheating</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have kidney problems</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have liver problems</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin‑dependent tumour.</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Risperdal.</p><p>&nbsp;</p><p>As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking Risperdal, your doctor may check your white blood cell counts.</p><p>&nbsp;</p><p>Risperdal may cause you to gain weight. Significant weight gain may adversely affect your health. Your doctor should regularly measure your body weight.</p><p>&nbsp;</p><p>As diabetes mellitus or worsening of pre‑existing diabetes mellitus have been seen with patients taking Risperdal, your doctor should check for signs of high blood sugar. In patients with pre‑existing diabetes mellitus blood glucose should be monitored regularly.</p><p>&nbsp;</p><p>Risperdal commonly raises levels of a hormone called &quot;prolactin&quot;. This may cause side effects such as menstrual disorders or fertility problems in women, breast swelling in men (see Possible side effects). If such side effects occur, evaluation of the prolactin level in the blood is recommended.</p><p>&nbsp;</p><p>During an operation on the eye for cloudiness of the lens (cataract), the pupil (the black circle in the middle of your eye) may not increase in size as needed. Also, the iris (the coloured part of the eye) may become floppy during surgery and that may lead to eye damage. If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.</p><p>&nbsp;</p><p><strong>Elderly people with dementia</strong></p><p>In elderly patients with dementia, there is an increased risk of stroke. You should not take risperidone (that is the active substance of the drug) if you have dementia caused by stroke. During treatment with risperidone you should frequently see your doctor.</p><p>Medical treatment should be sought straight away if you or your caregiver notice a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke.</p><p>&nbsp;</p><p>Risperidone alone or taken with furosemide may increase the risk of stroke or death in elderly people with dementia.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Before treatment is started for conduct disorder, other causes of aggressive behaviour should have been ruled out.</p><p>If during treatment with risperidone tiredness occurs, a change in the time of administration might improve attention difficulties.</p><p>Before treatment is started your, or your child&rsquo;s body weight may be measured and it may be regularly monitored during treatment.</p><p>A small and inconclusive study has reported an increase in height in children who took risperidone, but whether this is an effect of the drug or due to some other reason is not known.</p><p>&nbsp;</p><p><strong>Other medicines and Risperdal</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p><strong>It is especially important to talk to your doctor or pharmacist if you are taking any of the following</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines that work on your brain such as to help you calm down (benzodiazepines) or some medicines for pain (opiates), medicines for allergy (some antihistamines), as risperidone may increase the sedative effect of all of these</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines that may change the electrical activity of your heart, such as medicines for malaria, heart rhythm problems, allergies (antihistamines), some antidepressants or other medicines for mental problems</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines that cause a slow heart beat</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines that cause low blood potassium (such as certain diuretics)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines to treat raised blood pressure. Risperdal can lower blood pressure</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines for Parkinson&#39;s disease (such as levodopa)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that increase the activity of the central nervous system (psychostimulants, such as methylphenidate)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Water tablets (diuretics) used for heart problems or swelling of parts of your body due to a build-up of too much fluid (such as furosemide or chlorothiazide). Risperdal taken by itself or with furosemide, may have an increased risk of stroke or death in elderly people with dementia.</p><p>&nbsp;</p><p><strong>The following medicines may reduce the effect of risperidone</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Rifampicin (a medicine for treating some infections)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Carbamazepine, phenytoin (medicines for epilepsy)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Phenobarbital.</p><p>If you start or stop taking such medicines you may need a different dose of risperidone.</p><p>&nbsp;</p><p><strong>The following medicines may increase the effect of risperidone</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Quinidine (used for certain types of heart disease)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Antidepressants such as paroxetine, fluoxetine, tricyclic antidepressants</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Medicines known as beta‑blockers (used to treat high blood pressure)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Phenothiazines (such as medicines used to treat psychosis or to calm down)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Cimetidine, ranitidine (blockers of the acidity of stomach)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Itraconazole and ketoconazole (medicines for treating fungal infections)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Certain medicines used in the treatment of HIV/AIDS, such as ritonavir</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Verapamil, a medicine used to treat high blood pressure and/or abnormal heart rhythm</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sertraline and fluvoxamine, medicines used to treat depression and other psychiatric disorders.</p><p>If you start or stop taking such medicines you may need a different dose of risperidone.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Risperdal.</p><p>&nbsp;</p><p><strong>Risperdal with food, drink and alcohol</strong></p><p>You can take this medicine with or without food. You should avoid drinking alcohol when taking Risperdal.</p><p>&nbsp;</p><p><strong>Pregnancy, breast‑feeding and fertility</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will decide if you can take it</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The following symptoms may occur in newborn babies, of mothers that have used Risperdal in the last trimester (last three months of their pregnancy): shaking, muscle stiffness, and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Risperdal can raise your levels of a hormone called &quot;prolactin&quot; that may impact fertility (see Possible side effects).</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Dizziness, tiredness, and vision problems may occur during treatment with Risperdal. Do not drive or use any tools or machines without talking to your doctor first.</p><p>&nbsp;</p><p><strong>Risperdal film‑coated tablets contain lactose and Sodium</strong></p><p>The film‑coated tablets contain lactose, a type of sugar. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p><strong>Risperdal</strong> <strong>2&nbsp;mg and 6mg film‑coated tablets also contain sunset yellow (E110)</strong> that may cause allergic reactions.</p><p>&nbsp;</p><p><strong>Risperdal oral solution contains benzoic acid (E 210) and Sodium.</strong></p><p>This medicine contains 2&nbsp;mg benzoic acid in each 1&nbsp;ml of oral solution. Benzoic acid may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4&nbsp;weeks old).</p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say, essentially &lsquo;sodium free&rsquo;.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>The recommended dose is as follows:</strong></p><p><strong><em><u>For the treatment of schizophrenia</u></em></strong></p><p><strong><em>Adults</em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The usual starting dose is 2&nbsp;mg per day, this may be increased to 4&nbsp;mg per day on the second day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your dose may then be adjusted by your doctor depending on how you respond to the treatment</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Most people feel better with daily doses of 4 to 6&nbsp;mg</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>This total daily dose can be divided into either one or two doses a day. Your doctor will tell you which is the best for you.</p><p>&nbsp;</p><p><strong><em>Elderly people</em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your starting dose will normally be 0.5&nbsp;mg twice a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your dose may then be gradually increased by your doctor to 1&nbsp;mg to 2&nbsp;mg twice a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your doctor will tell you which is the best for you.</p><p><strong>&nbsp;</strong></p><p><strong><em><u>For the treatment of mania</u></em></strong></p><p><strong><em>Adults</em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your starting dose will usually be 2&nbsp;mg once a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your dose may then be gradually adjusted by your doctor depending on how you respond to the treatment</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Most people feel better with doses of 1&nbsp;to 6&nbsp;mg once a day.</p><p><strong>&nbsp;</strong></p><p><strong><em>Elderly people</em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your starting dose will usually be 0.5&nbsp;mg twice a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your dose may then be gradually adjusted by your doctor to 1&nbsp;mg to 2&nbsp;mg twice a day depending on how much you respond to the treatment.</p><p>&nbsp;</p><p><strong><em><u>For the treatment of long‑standing aggression in people with Alzheimer&rsquo;s dementia</u></em></strong></p><p><strong><em>Adults (including elderly people)</em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your starting dose will normally be 0.25&nbsp;mg (0.25 ml of Risperdal oral solution 1 mg/ml) twice a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Your dose may then be gradually adjusted by your doctor depending on how you respond to the treatment</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Most people feel better with 0.5&nbsp;mg twice a day. Some patients may need 1&nbsp;mg twice a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Treatment duration in patients with Alzheimer&rsquo;s dementia should be not more than 6&nbsp;weeks.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Children and adolescents under 18&nbsp;years old should not be treated with Risperdal for schizophrenia or mania.</p><p><strong>&nbsp;</strong></p><p><strong><em><u>For the treatment of conduct disorder</u></em></strong></p><p>The dose will depend on your child&rsquo;s weight:</p><p>&nbsp;</p><p><strong><em><u>For children who weigh less than 50&nbsp;kg</u></em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The starting dose will normally be 0.25&nbsp;mg (0.25 ml of Risperdal oral solution 1 mg/ml) once a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The dose may be increased every other day in steps of 0.25&nbsp;mg per day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The usual maintenance dose is 0.25&nbsp;mg to 0.75&nbsp;mg (0.25 ml to 0.75 ml of Risperdal oral solution 1 mg/ml) once a day.</p><p>&nbsp;</p><p><strong><em><u>For children who weigh 50&nbsp;kg or more</u></em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The starting dose will normally be 0.5&nbsp;mg once a day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The dose may be increased every other day in steps of 0.5&nbsp;mg per day</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The usual maintenance dose is 0.5&nbsp;mg to 1.5&nbsp;mg once a day.</p><p>&nbsp;</p><p>Treatment duration in patients with conduct disorder should be not more than 6&nbsp;weeks.</p><p>&nbsp;</p><p>Children under 5&nbsp;years old should not be treated with Risperdal for conduct disorder.</p><p>&nbsp;</p><p><strong>People with kidney or liver problems</strong></p><p>Regardless of the disease to be treated, all starting doses and following doses of risperidone should be halved. Dose increases should be slower in these patients.</p><p>Risperidone should be used with caution in this patient group.</p><p>&nbsp;</p><p>For lower doses Risperdal film coated tablets 0.5 mg, 1 mg or 2 mg and Risperdal 1 mg/ml oral solution is available.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>FOR ORAL USE</p><p>&nbsp;</p><p><strong><em><u>Risperdal film‑coated tablets</u></em></strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>You should swallow your tablet with a drink of water</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>The score line is only there to help you break the tablet if you have difficulty swallowing it whole.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong><em><u>Risperdal oral solution</u></em></strong></p><p>Take the solution with liquid but not together with black or green tea.</p><p>The solution comes with a syringe (pipette). This should be used to help you measure the exact amount of medicine you need.</p><p>Follow these steps:</p><p><img alt="" width="708" height="648" src="data:image/jpeg;base64,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" /></p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Holding the bottom ring, remove the entire syringe from the bottle (Figure 4)</p><p><img alt="" width="373" height="333" src="data:image/jpeg;base64,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" /></p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Empty the syringe into any non‑alcoholic drink, except for tea. Slide the upper ring down</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the bottle</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse the syringe with some water.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Risperdal than you should</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>See a doctor right away. Take the medicine pack with you</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>In case of overdose you may feel sleepy or tired, or have abnormal body movements, problems standing and walking, feel dizzy due to low blood pressure, or have abnormal heartbeats or fits.</p><p>&nbsp;</p><p><strong>If you forget to take Risperdal</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue as usual. If you miss two or more doses, contact your doctor</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Risperdal</strong></p><p>You should not stop taking this medicine unless told to do so by your doctor. Your symptoms may return. If your doctor decides to stop this medicine, your dose may be decreased gradually over a few days.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately if you </strong><strong>experience any of the following</strong><strong> uncommon side effects (may affect up to 1 in 100&nbsp;people)</strong><strong>:</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Have dementia and experience a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke.</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Experience tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body). Tell your doctor immediately if you experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of Risperdal may be needed.</p><p><strong>Tell your doctor immediately if you </strong><strong>experience any of the following</strong><strong> rare side effects (</strong><strong>may affect up to 1 in 1,000&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty breathing. If you notice any of these symptoms seek medical advice immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called &ldquo;Neuroleptic Malignant Syndrome&rdquo;). Immediate medical treatment may be needed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are a man and experience prolonged or painful erection. This is called priapism. Immediate medical treatment may be needed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Experience severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash or drop in blood pressure.</p><p>&nbsp;</p><p>&nbsp;</p><p>The following other side effects may also happen:</p><p><strong>Very common side effects (</strong><strong>may affect more than 1 in 10&nbsp;people):</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Difficulty falling or staying asleep</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Parkinsonism: This condition may include: slow or impaired movement, sensation of stiffness or tightness of the muscles (making your movements jerky), and sometimes even a sensation of movement &quot;freezing up&quot; and then restarting. Other signs of parkinsonism include a slow shuffling walk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Feeling sleepy, or less alert</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Headache.</p><p><strong>&nbsp;</strong></p><p><strong>Common side effects (</strong><strong>may affect up to 1 in 10&nbsp;people):</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Pneumonia, infection of the chest (bronchitis), common cold symptoms, sinus infection, urinary tract infection, ear infection, feeling like you have the flu</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Raised levels of a hormone called &quot;prolactin&quot; found in a blood test (which may or may not cause symptoms). Symptoms of high prolactin occur uncommonly and may include in men breast swelling, difficulty in getting or maintaining erections, decreased sexual desire or other sexual dysfunction. In women they may include breast discomfort, leakage of milk from the breasts, missed menstrual periods, or other problems with your cycle or fertility problems</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Weight gain, increased appetite, decreased appetite</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sleep disorder, irritability, depression, anxiety, restlessness</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Dystonia: This is a condition involving slow or sustained involuntary contraction of muscles. While it can involve any part of the body (and may result in abnormal posture), dystonia often involves muscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Dizziness</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Dyskinesia: This is a condition involving involuntary muscle movements, and can include repetitive, spastic or writhing movements, or twitching</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Tremor (shaking)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Blurry vision, eye infection or &quot;pink eye&quot;</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Rapid heart rate, high blood pressure, shortness of breath</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sore throat, cough, nosebleeds, stuffy nose</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhea, indigestion, dry mouth, toothache</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Rash, skin redness</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Muscle spasms, bone or muscle ache, back pain, joint pain</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Incontinence (lack of control) of urine</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Swelling of the body, arms or legs, fever, chest pain, weakness, fatigue (tiredness), pain</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Fall.</p><p>&nbsp;</p><p><strong>Uncommon side effects (</strong><strong>may affect up to 1 in 100&nbsp;people):</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Infection of the breathing passages, bladder infection, eye infection, tonsillitis, fungal infection of the nails, infection of the skin, an infection confined to a single area of skin or part of the body, viral infection, skin inflammation caused by mites</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Decrease in the type of white blood cells that help to protect you against infection, white blood cell count decreased, decrease in platelets (blood cells that help you stop bleeding), anaemia, decrease in red blood cells, increase in eosinophils (a type of white blood cell) in your blood</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Allergic reaction</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Diabetes or worsening of diabetes, high blood sugar, excessive drinking of water</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Weight loss, loss of appetite resulting in malnutrition and low body weight</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Increased cholesterol in your blood</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Elated mood (mania), confusion, decreased sexual drive, nervousness, nightmares</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Unresponsive to stimuli, loss of consciousness, low level of consciousness</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Convulsion (fits), fainting</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>A restless urge to move parts of your body, balance disorder, abnormal coordination, dizziness upon standing, disturbance in attention, problems with speech, loss or abnormal sense of taste, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness skin</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Oversensitivity of the eyes to light, dry eye, increased tears, redness of the eyes</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sensation of spinning (vertigo), ringing in the ears, ear pain</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Atrial fibrillation (an abnormal heart rhythm), an interruption in conduction between the upper and lower parts of the heart, abnormal electrical conduction of the heart, prolongation of the QT interval from your heart, slow heart rate, abnormal electrical tracing of the heart (electrocardiogram or ECG), a fluttering or pounding feeling in your chest (palpitations)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Low blood pressure, low blood pressure upon standing (consequently, some people taking Risperdal may feel faint, dizzy, or may pass out when they stand up or sit up suddenly, flushing</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Pneumonia caused by inhaling food, lung congestion, congestion of breathing passages, crackly lung sounds, wheezing, voice disorder, breathing passage disorder</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Stomach or intestinal infection, stool incontinence, very hard stool, difficulty swallowing, excessive passing of gas or wind</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Hives (or &quot;nettle rash&quot;), itching, hair loss, thickening of skin, eczema, dry skin, skin discolouration, acne, flaky, itchy scalp or skin, skin disorder, skin lesion</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>An increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Abnormal posture, joint stiffness, joint swelling, muscle weakness, neck pain</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Frequent passing of urine, inability to pass urine, pain when passing urine</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Erectile dysfunction, ejaculation disorder</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Loss of menstrual periods, missed menstrual periods or other problems with your cycle (females)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Development of breasts in men, leakage of milk from the breasts, sexual dysfunction, breast pain, breast discomfort, vaginal discharge</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Swelling of the face, mouth, eyes, or lips</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Chills, an increase in body temperature</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>A change in the way you walk</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Feeling thirsty, feeling unwell, chest discomfort, feeling &quot;out of sorts&quot;, discomfort</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Increased liver transaminases in your blood, increased GGT (a liver enzyme called gamma‑glutamyltransferase) in your blood, increased liver enzymes in your blood</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Procedural pain.</p><p>&nbsp;</p><p><strong>Rare side effects (</strong><strong>may affect up to 1 in 1,000&nbsp;people):</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Infection</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Inappropriate secretion of a hormone that controls urine volume</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sleep walking</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sleep-related eating disorder</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sugar in the urine, low blood sugar, high blood triglycerides (a fat)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Lack of emotion, inability to reach orgasm</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not moving or responding while awake (catatonia)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Blood vessel problems in the brain</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Coma due to uncontrolled diabetes</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Shaking of the head</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Glaucoma (increased pressure within the eyeball), problems with movement of your eyes, eye rolling, eyelid margin crusting</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Eye problems during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken Risperdal. If you need to have cataract surgery, be sure to tell your eye doctor if you take or have taken this medicine</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Dangerously excessive intake of water</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Irregular heart beat</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Trouble breathing during sleep (sleep apnea), fast, shallow breathing</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Inflammation of the pancreas, a blockage in the bowels</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Swollen tongue, chapped lips, rash on skin related to drug</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Dandruff</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Breakdown of muscle fibers and pain in muscles (rhabdomyolysis)</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>A delay in menstrual periods, enlargement of the glands in your breasts, breast enlargement, discharge from the breasts</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Increased insulin (a hormone that controls blood sugar levels) in your blood</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Hardening of the skin</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Decreased body temperature, coldness in arms and legs</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Symptoms of drug withdrawal</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Yellowing of the skin and the eyes (jaundice).</p><p>&nbsp;</p><p><strong>Very rare side effects (</strong><strong>may affect up to 1 in 10,000&nbsp;people):</strong></p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Life threatening complications of uncontrolled diabetes</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Serious allergic reaction with swelling that may involve the throat and lead to difficulty breathing</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Lack of bowel muscle movement that causes blockage.</p><p>&nbsp;</p><p><strong>Not known (frequency cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe or life‑threatening rash with blisters and peeling skin that may start in and around the mouth, nose, eyes, and genitals and spread to other areas of the body (Stevens‑Johnson syndrome or toxic epidermal necrolysis).</p><p>&nbsp;</p><p>The following side effect has been seen with the use of another medicine called paliperidone that is very similar to risperidone, so these can also be expected with Risperdal: Rapid heartbeat upon standing.</p><p>&nbsp;</p><p><strong>Additional side effects in children and adolescents</strong></p><p>In general, side effects in children are expected to be similar to those in adults.</p><p>The following side effects were reported more often in children and adolescents (5 to 17&nbsp;years) than in adults: feeling sleepy, or less alert, fatigue (tiredness), headache, increased appetite, vomiting, common cold symptoms, nasal congestion, abdominal pain, dizziness, cough, fever, tremor (shaking), diarrhoea, and incontinence (lack of control) of urine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister, carton, or bottle. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p><strong>Risperdal film‑coated tablets</strong></p><p>Blister packs: Store in the original package in order to protect from light.</p><p><strong>&nbsp;</strong></p><p><strong>Risperdal oral solution</strong></p><p>&nbsp;</p><p>Do not refrigerate or freeze.</p><p>&nbsp;</p><p>Once the bottle is opened, any unused portion of Risperdal oral solution should be discarded after 3&nbsp;months.</p><p>&nbsp;</p><p>Do not throw away any medicines in wastewater (e.g. in the toilet or washbasin). Ask in your pharmacy how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Risperdal contains</strong></p><p>The active substance is risperidone</p><p>&nbsp;</p><p>Each Risperdal film‑coated tablet contains either 1&nbsp;mg, 2&nbsp;mg, 3&nbsp;mg or 4&nbsp;mg of risperidone.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>Risperdal 1&nbsp;mg film‑coated tablets:</p><p><em><u>Tablet core: </u></em>Lactose monohydrate, Maize starch, Cellulose microcrystalline (E460), Hypromellose (E464), Magnesium stearate, Silica colloidal anhydrous, Sodium laurilsulfate.</p><p><em><u>Film‑coating</u></em>: Hypromellose (E464), Propylene glycol (E490).</p><p>&nbsp;</p><p>Risperdal 2&nbsp;mg film‑coated tablets:</p><p><em><u>Tablet core: </u></em>Lactose monohydrate, Maize starch, Cellulose microcrystalline (E460), Hypromellose (E464), Magnesium stearate, Silica colloidal anhydrous, Sodium laurilsulfate.</p><p><em><u>Film‑coating</u></em>: Hypromellose (E464), Propylene glycol (E490), Titanium dioxide (E171), Talc (E553B), Orange yellow S aluminium lake (Sunset yellow) E110.</p><p>&nbsp;</p><p>Risperdal 3&nbsp;mg film‑coated tablets:</p><p><em><u>Tablet core: </u></em>Lactose monohydrate, Maize starch, Cellulose microcrystalline (E460), Hypromellose (E464, Magnesium stearate, Silica colloidal anhydrous, Sodium laurilsulfate.</p><p><em><u>Film‑coating: </u></em>Hypromellose (E464), Propylene glycol (E490), Titanium dioxide (E171), Talc (E553B), Quinoline yellow (E104).</p><p>&nbsp;</p><p>Risperdal 4&nbsp;mg film‑coated tablets:</p><p><em><u>Tablet core: </u></em>Lactose monohydrate, Maize starch, Cellulose microcrystalline (E460), Hypromellose (E464), Magnesium stearate, Silica colloidal anhydrous, Sodium laurilsulfate.</p><p><em><u>Film‑coating:</u></em> Hypromellose (E464), Propylene glycol (E490), Titanium dioxide (E171), Talc<sup> </sup>(E553B), Quinoline yellow (E104), Indigotindisulfonate aluminium lake (E132).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>1&nbsp;ml Risperdal oral solution contains 1&nbsp;mg risperidone.</p><p>The other ingredients are:</p><p>Tartaric acid (Ph.Eur.), Benzoic acid, Sodium hydroxide, Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Risperdal looks like and contents of the pack
Risperdal film coated tablets are packaged in PVC/LDPE/PVDC/aluminium foil blisters and HDPE bottles with PP screw cap.

Risperdal film coated tablets
●	1 mg risperidone are white, half scored, oblong, biconvex film coated tablets of 10.5 mm x 5 mm
●	2 mg risperidone are orange, half scored, oblong, biconvex film coated tablets of 10.5 mm x 5 mm
●	3 mg risperidone are yellow, half scored, oblong, biconvex film coated tablets of 13.5 mm x 5 mm
●	4 mg risperidone are green, half scored, oblong, biconvex film coated tablets of 15 mm x 6.5 mm

Film coated tablets are etched on one side with RIS 1, RIS 2, RIS 3,  and RIS 4 respectively. Additionally, JANSSEN may be etched on the other side.

Pack sizes
Risperdal film coated tablets are available in the following pack sizes:
●	1 mg: blister packs containing 6, 20, 50, 60, or 100 tablets and bottles containing 500 tablets
●	2 mg: blister packs containing 10, 20, 50, 60, or 100 tablets and bottles containing 500 tablets
●	3 mg: blister packs containing 20, 50, 60, or 100 tablets
●	4 mg: blister packs containing 10, 20, 30, 50, 60, or 100 tablets
Not all pack sizes may be marketed.

Oral solution
Risperdal solution 100 mg/ml is supplied in an amber bottle with a child resistant cap containing 30 ml, 60 ml, 100 ml or 120 ml; of a clear, colourless liquid. A dosing pipette (certificated medical device) is also provided.

The pipette supplied with the bottle size of 30 ml, 60 ml and 100 ml is graduated in milligrams and millilitres with a minimum volume of 0.25 ml and a maximum volume of 3 ml. Graduation marks in 0.25 ml (equals 0.25 mg oral solution) increments up to 3 ml (equals 3 mg oral solution) are printed on this pipette. The pipette supplied with the bottle size of 120 ml is graduated in milligrams and millilitres with a minimum volume of 0.25 ml and a maximum volume of 4 ml. Graduation marks in 0.25 ml (equals 0.25 mg oral solution) increments up to 4 ml (equals 4 mg oral solution) are printed on this pipette.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Marketing Authorisation Holder</strong></p><p>Janssen-Cilag NV Antwerpseweg 15-17 B-2340 Beerse, Belgium</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p><u>Risperdal Tablets:<strong> </strong></u>Janssen-Cilag SpA, Via C. Janssen (loc. BORGO S. MICHELE)-04100 LATINA (LT)-Italy</p><p><u>Risperdal Oral solution:</u> Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340,Beerse Belgium.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in 19 August 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يُستخدم دواء ريسبردال لعلاج ما يلي:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الفصام، حيث قد ترى أو تسمع أو تشعر بأشياء غير موجودة أو تصدق أشياء غير حقيقية، أو تشعر بالريبة أو الارتباك بشكل غير معتاد.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهوس، حيث قد تشعر بسعادة بالغة أو الابتهاج أو الاضطراب أو الحماسة أو النشاط الزائد. تظهر حالة الهوس مصحوبة بمرض يطلق عيه &quot;الاضطراب ثنائي القطب&quot;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج العدوان النفسي طويل المدى في فترة زمنية قصيرة (حتى 6 أسابيع) في الأشخاص الذين يعانون من الخرف المصاحب لمرض ألزهايمر والذين يؤذون أنفسهم أو يؤذون الآخرين. ينبغي استخدام علاجات بديلة (لا تحتوي على أدوية) قبل ذلك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج العدوانية طويلة المدى في فترة زمنية قصيرة (حتى 6&nbsp;أسابيع) في الأطفال المعاقين ذهنيًا (الذين تبلغ أعمارهم 5&nbsp;سنوات على الأقل) والمراهقين الذين يعانون من اضطراب السلوك.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يساعد دواء ريسبردال على تخفيف الأعراض المصاحبة لمرضك ومنع ظهور الأعراض مرة أخرى.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول </strong><strong>دواء ريسبردال</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية للريسبيردون أو الصبغة الصفراء مثل لون غروب الشمس أو لأي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6).</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن ما ذكر أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل استخدام دواء ريسبردال.</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول دواء ريسبردال إذا:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلة في القلب. وتتضمن الأمثلة عدم انتظام ضربات القلب أو إذا كنت عرضة لانخفاض ضغط الدم أو إذا كنت تستخدم أدوية لضغط الدم. قد يؤدي دواء ريسبردال إلى حدوث انخفاض في ضغط الدم. ربما يلزم تعديل الجرعة المحددة.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرفت على أي عوامل قد تؤدي إلى إصابتك بالسكتة، مثل ارتفاع ضغط الدم أو الاضطراب القلبي الوعائي أو مشكلات الأوعية الدموية في الدماغ.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت في أي وقت لحركات لا إرادية في اللسان والفم والوجه</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت بحالة مرضية مؤخرًا صاحبتها أعراض مثل ارتفاع درجة الحرارة أو تصلب العضلات أو التعرق أو انخفاض مستوى الوعي (تعرف أيضًا بالمتلازمة الخبيثة للدواء المضاد للذهان)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من داء باركنسون أو الخرف</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعلم أنك كنت تعاني من انخفاض في مستويات كرات الدم البيضاء في الماضي (التي قد تكون أو لا تكون نجمت عن تناول أدوية أخرى)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالسكري</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من الصرع</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت ذكرًا وكنت تعاني مؤخرًا من الانتصاب لفترات طويلة أو الانتصاب المؤلم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في السيطرة على درجة حرارة جسمك أو ارتفاع زائد في درجة حرارة جسمك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الكلى</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الكبد</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مستوى عالٍ بشكل مفرط من هرمون البرولاكتين في الدم أو إذا كنت مصابًا بورم محتمل قائم على هرمون البرولاكتين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك أنت أو أي شخص آخر في عائلتك سجل من الجلطات الدموية، حيث ترتبط مضادات الذهان بتكوين الجلطات الدموية.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن أيًّا مما ذُكِرَ أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل استخدام دواء ريسبردال.</p><p>&nbsp;</p><p dir="RTL">نظرًا لأن انخفاض أعداد نوع معين بشكل خطير من كرات الدم البيضاء اللازمة لمكافحة العدوى في الدم نادرًا ما يشاهد مع المرضى الذين يتناولون دواء ريسبردال، فقد يفحص طبيبك أعداد خلايا الدم البيضاء لديك.</p><p>&nbsp;</p><p dir="RTL">قد يتسبب دواء ريسبردال في زيادة وزنك. وقد تؤثر زيادة الوزن الكبيرة سلبًا على صحتك. يتعين على طبيبك قياس وزن جسمك بانتظام.</p><p>&nbsp;</p><p dir="RTL">في حالة وجود مرض السكري أو تفاقم السكري الموجود مسبقًا في المرضى الذين يتناولون دواء ريسبردال، ينبغي على طبيبك البحث عن علامات ارتفاع نسبة السكر في الدم. ويجب فحص نسبة الجلوكوز في الدم لدى المرضى المصابين بالسكّري من قبل بانتظام.</p><p>&nbsp;</p><p dir="RTL">يرفع عادة دواء ريسبردال مستويات الهرمون المسمى &quot;البرولاكتين&quot;. قد يتسبب هذا في حدوث آثار جانبية تتمثل في اضطرابات في دورة الحيض أو مشكلات خصوبة لدى النساء، أو تورم الصدر لدى الرجال (راجع الآثار الجانبية المحتملة). في حالة حدوث هذه الآثار الجانبية، يوصى بتقييم مستوى البرولاكتين في الدم.</p><p>&nbsp;</p><p dir="RTL">عند إجراء عملية جراحية في العين لإزالة عتامة عدسة العين (المياه البيضاء)، قد لا يزداد حجم حدقة العين (الدائرة السوداء في منتصف العين) كما هو مطلوب. وقد تصبح أيضًا القزحية (الجزء الملون من العين) رخوة أثناء الجراحة مما قد يتسبب في إصابة العين بالأضرار. وإذا كنت تخطط لإجراء عملية جراحية في عينيك، فتأكد من إبلاغ طبيب العيون المعالج من أنك تتناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>كبار السن الذين يعانون من الخرف</strong></p><p dir="RTL">في المرضى من كبار السن الذين يعانون من الخرف، يتزايد خطر الإصابة بالسكتة الدماغية. ويتعين عليك عدم تناول الريسبيريدون (والذي هو المادة الفعالة لهذا الدواء) إذا كنت تعاني من الخرف الذي سببته السكتة الدماغية.أثناء فترة العلاج بدواء الريسبيريدون، يتعين عليك مراجعة الطبيب بصورة دورية.</p><p dir="RTL">ينبغي طلب العلاج الطبي مباشرة إذا لاحظت أنت أو مقدم الرعاية الخاص بك تغييرًا مفاجئًا في حالتك العقلية أو حدوث ضعف أو تنميل مفاجئ في وجهك أو ذراعيك أو ساقيك وخصوصًا في جانب واحد، أو صعوبة في الكلام، حتى لو لفترة زمنية قصيرة. قد تكون هذه الأمور علامات على السكتة الدماغية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي تناول ريسبيريدون بمفرده أو مع فيوروسيميد إلى زيادة خطر الإصابة بالسكتة الدماغية أو الوفاة لدى كبار السن المصابين بالخرف.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">قبل بدء علاج الاضطراب السلوكى، يتعين استثناء الأسباب الأخرى التي ينتج عنها السلوك العدواني.</p><p dir="RTL">إذا تسبب دواء الريسبيريدون في حدوث تعب في أثناء فترة العلاج، فقد يؤدي تغيير وقت تناول الدواء إلى تحسين صعوبات الانتباه.</p><p dir="RTL">قبل بدء فترة العلاج، قد يتم قياس وزنك أو وزن طفلك وقد تتم مراقبته بانتظام أثناء العلاج.</p><p dir="RTL">تطرقت دراسة بسيطة وغير حاسمة إلى حدوث زيادة في طول الأطفال الذين تناولوا دواء الريسبيريدون، لكن لا يمكن الجزم بأن ذلك ناتج عن تأثير الدواء أو عن بعض الأمور الأخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى </strong><strong>وريسبردال</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>من المهم تحديدًا استشارة طبيبك أو الصيدلي إذا كنت تتناول أيًّا مما يلي</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على الدماغ مثل الأدوية المهدئة (البنزوديازيبين) أو بعض الأدوية التي تستخدم كمسكن (الأفيونات)، أو&nbsp;الأدوية التي تعالج الحساسية (بعض مضادات الهيستامين)، حيث قد يزيد دواء الريسبيريدون من الأثر المهدئ لكل هذه</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تغير من النشاط الكهربي للقلب، مثل الأدوية المعالجة للملاريا أو مشكلات ضربات القلب أو الحساسية (مضادات&nbsp;الهيستامين) أو بعض مضادات الاكتئاب أو غيرها من الأدوية التي تعالج المشكلات العقلية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤدي إلى بطء ضربات القلب</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤدي إلى انخفاض البوتاسيوم في الدم (مثل بعض مدرات البول)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تعالج ارتفاع ضغط الدم. يمكن أن يؤدي تناول دواء ريسبردال إلى انخفاض ضغط الدم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المعالجة لداء باركنسون (مثل الليفودوبا)</p><p dir="RTL"><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong>الأدوية التي تزيد من نشاط الجهاز العصبي المركزي (المنبهات النفسية مثل ميثيل الفينيدات)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص المياه (مدرات البول) المستخدمة في علاج مشكلات القلب أو تورم أجزاء من جسمك الناتج عن تراكم مقدار كبير من السائل (مثل الفوروسيميد أو الكلوروثيازيد). قد يؤدي دواء ريسبردال الذي يتم تناوله وحده أو مع الفوروسيميد إلى تزايد خطر الإصابة بالسكتة الدماغية أو حدوث الوفاة في كبار السن الذين يعانون من الخرف.</p><p>&nbsp;</p><p dir="RTL"><strong>قد تقلل الأدوية التالية من تأثير دواء الريسبيريدون</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريفامبيسين (وهو دواء لعلاج بعض الالتهابات)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكربامازيبين والفنيتوين (أدوية لعلاج الصرع)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينوباربيتال.</p><p dir="RTL">إذا بدأت في تناول هذه الأدوية أو توقفت عن تناولها، فقد تحتاج إلى جرعات مختلفة من الريسبيريدون.</p><p>&nbsp;</p><p dir="RTL"><strong>قد تزيد الأدوية التالية من تأثير دواء الريسبيريدون</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكينيدين (يُستخدم في علاج أنواع معينة من أمراض القلب)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب مثل الباروكسيتين والفلوكسيتين ومضادات الاكتئاب ثلاثية الحلقات</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل حاصرات بيتا (تُستخدم في علاج ارتفاع ضغط الدم)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينوثيازين (مثل الأدوية المستخدمة في علاج الذهان أو التهدئة)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيميتيدين والرانتيدين (حاصرات لحموضة المعدة)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإيتراكونازول والكيتوكونازول (أدوية لعلاج الالتهابات الفطرية)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة في علاج فيروس العوز المناعي البشري/متلازمة نقص المناعة المكتسبة، مثل الريتونافير</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفيراباميل، دواء يُستخدم في علاج ارتفاع ضغط الدم و/أو عدم انتظام ضربات القلب</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيرترالين والفلوفوكسامين، أدوية تُستخدم في علاج الاكتئاب والاضطرابات النفسية الأخرى.</p><p dir="RTL">إذا بدأت في تناول هذه الأدوية أو توقفت عن تناولها، فقد تحتاج إلى جرعات مختلفة من الريسبيريدون.</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن أيًّا مما ذُكِرَ أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل استخدام دواء ريسبردال.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول دواء ريسبردال مع الطعام والشراب والكحول</strong></p><p dir="RTL">يمكنك تناول هذا الدواء مع الطعام أو بدونه. ينبغي عليك تجنب شرب الكحول عند تناول دواء ريسبردال.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو ترضعين، أو تعتقدين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فعليكِ استشارة طبيبك أو الصيدلي طلبًا للنصيحة قبل تناول هذا الدواء. سيحدد طبيبك المعالج قراره بشأن تناولك لهذا الدواء.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وقد تحدث الأعراض التالية لدى الأطفال حديثي الولادة لأمهات استخدمن ريسبردال في الثلث الأخير من الحمل (الأشهر الثلاثة الأخيرة من حملهن): رعشة وتصلب العضلات و/أو الضعف والنعاس والهياج ومشكلات في التنفس وصعوبة في الرضاعة. إذا&nbsp;ظهرت أي من هذه الأعراض على طفلك، فعليك الاتصال بطبيبك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يرفع دواء ريسبردال مستويات الهرمون المسمى &quot;البرولاكتين&quot; الذي قد يؤثر على الخصوبة (راجع الآثار الجانبية المحتملة).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تحدث دوخة أو إعياء أو مشكلات في الرؤية أثناء العلاج بدواء ريسبردال. تجنب القيادة أو استخدام أي أدوات أو أجهزة دون استشارة طبيبك أولاً.</p><p>&nbsp;</p><p dir="RTL"><strong>تحتوي أقراص دواء ريسبردال المغلفة بطبقة رقيقة على اللاكتوز</strong> <strong>والصوديوم</strong></p><p dir="RTL">تحتوي الأقراص المغلفة بطبقة رقيقة على اللاكتوز، أحد أنواع السكر. إذا أخبرك طبيبك بأن لديك حساسية مفرطة لبعض السكريات، فاتصل به قبل تناول هذا المنتج الدوائي.</p><p>&nbsp;</p><p dir="RTL"><strong>تحتوي أيضًا أقراص دواء ريسبردال</strong> <strong>بتركيز 2&nbsp;مجم و6&nbsp;مجم المغلفة بطبقة رقيقة على مادة (</strong><strong>E110</strong><strong>)</strong> الصفراء مثل غروب الشمس التي تسبب ردود الفعل التحسسية.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي محلول ريسبردال الفموي على حمض البنزويك (</strong><strong>E 210</strong><strong>)</strong> <strong>والصوديوم.</strong><strong> </strong><strong>.</strong></p><p dir="RTL">يحتوي هذا الدواء على 2&nbsp;مجم من حمض البنزويك في كل 1&nbsp;مل من المحلول الفموي. قد يتسبب حمض البنزويك في زيادة اليرقان (اصفرار الجلد والعينين) في الأطفال حديثي الولادة (حتى عمر 4&nbsp;أسابيع).</p><p>&nbsp;</p><p>يحتوي هذا الدواء على أقل من 1 ملليمول من الصوديم (23 مجم) للجرعة، ما يعني أنه &quot;خالٍ من الصوديوم&quot; بشكلٍ أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما أخبرك الطبيب تمامًا. راجع الطبيب أو الصيدلي إذا لم تكن متأكدًا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة الموصى بها على النحو التالي:</strong></p><p dir="RTL"><strong><em><u>لعلاج مرض الفصام</u></em></strong></p><p dir="RTL"><strong><em>البالغون</em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المبدئية المعتادة هي 2 مجم في اليوم، قد تزداد في اليوم التالي لتصل إلى 4 مجم يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومن ثم قد يغير الطبيب جرعتك وفقًا لمدى استجابتك للعلاج</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يشعر معظم الأشخاص بتحسن مع الجرعات اليومية من 4 إلى 6 مجم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تقسيم هذه الجرعة الكلية إلى جرعة واحدة أو اثنتين يوميًا. سيخبرك طبيبك بالطريقة الأفضل لك.</p><p>&nbsp;</p><p dir="RTL"><strong><em>الأشخاص كبار السن</em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحدد الجرعة المبدئية المخصصة لك عادة بجرعة 0.5 مجم مرتين في اليوم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُزيد طبيبك بعد ذلك الجرعة المخصصة لك تدريجيًا لتصل إلى 1 مجم وإلى 2 مجم مرتين في اليوم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيبك بالطريقة الأفضل لك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><em><u>لعلاج مرض الهوس</u></em></strong></p><p dir="RTL"><strong><em>البالغون</em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحدد الجرعة المبدئية المخصصة لك عادة بجرعة 2 مجم مرة واحدة يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومن ثم قد يغير الطبيب جرعتك تدريجيًا وفقًا لمدى استجابتك للعلاج</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يشعر معظم الأشخاص بتحسن مع الجرعات من 1 إلى 6 مجم مرة واحدة يوميًا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><em>الأشخاص كبار السن</em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحدد الجرعة المبدئية المخصصة لك عادة بجرعة 0.5 مجم مرتين في اليوم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومن ثم قد يغير الطبيب جرعتك تدريجيًا إلى 1 مجم وإلى 2 مجم مرتين يوميًا وفقًا لمدى استجابتك للعلاج.</p><p>&nbsp;</p><p dir="RTL"><strong><em><u>لعلاج العدوان النفسي المستمر منذ فترة طويلة في الأشخاص الذين يعانون من الخرف المصاحب لمرض ألزهايمر</u></em></strong></p><p dir="RTL"><strong><em>البالغون (بما في ذلك كبار السن)</em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستكون جرعتك الأولية عادةً بتركيز 0.25&nbsp;مجم (0.25 مل من محلول ريسبردال الفموي 1 مجم/مل) مرتين يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومن ثم قد يغير الطبيب جرعتك تدريجيًا وفقًا لمدى استجابتك للعلاج</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يشعر معظم الأشخاص بتحسن مع الجرعة 0.5 مجم مرتين في اليوم. قد يحتاج بعض المرضى إلى تحديد جرعة 1 مجم مرتين في&nbsp;اليوم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي ألا تزيد فترة العلاج في المرضى الذين يعانون من الخرف المصاحب لمرض ألزهايمر عن 6 أسابيع.</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام للأطفال والمراهقين</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي استخدام دواء ريسبردال في علاج مرض الفصام والهوس في الأطفال والمراهقين الذين تقل أعمارهم عن 18&nbsp;سنة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><em><u>لعلاج الاضطراب السلوكي</u></em></strong></p><p dir="RTL">ستعتمد الجرعة على وزن طفلك:</p><p>&nbsp;</p><p dir="RTL"><strong><em><u>فيما يخص الأطفال الذين تقل أوزانهم عن 50 كجم</u></em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستكون الجرعة الأولية عادةً بتركيز 0.25&nbsp;مجم (0.25 مل من محلول ريسبردال الفموي 1 مجم/مل) مرة واحدة يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تزيد الجرعة كل يومين بمعدل 0.25 مجم يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح جرعة المداومة المعتادة من 0.25&nbsp;مجم إلى 0.75&nbsp;مجم (0.25 مل إلى 0.75 مل من محلول ريسبردال الفموي 1&nbsp;مجم/مل) مرة واحدة يوميًا.</p><p>&nbsp;</p><p dir="RTL"><strong><em><u>فيما يخص الأطفال الذين تبلغ أوزانهم 50 كجم أو أكثر</u></em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحدد الجرعة المبدئية عادة بـ 0.5 مجم مرة واحدة يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تزيد الجرعة كل يومين بمعدل 0.5 مجم يوميًا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح جرعة المداومة المعتادة من 0.5 مجم إلى 1.5 مجم مرة واحدة في اليوم.</p><p>&nbsp;</p><p dir="RTL">ينبغي ألا تزيد فترة العلاج في المرضى الذين يعانون من الاضطراب السلوكي عن 6&nbsp;أسابيع.</p><p>&nbsp;</p><p dir="RTL">لا ينبغي استخدام دواء ريسبردال في علاج الاضطراب السلوكي في الأطفال الذين تقل أعمارهم عن 5&nbsp;سنوات.</p><p>&nbsp;</p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشكلات في الكلية أو الكبد</strong></p><p dir="RTL">بغض النظر عن المرض المراد علاجه، ينبغي خفض جميع الجرعات المبدئية والجرعات التالية لها من دواء الريسبيريدون إلى النصف. ينبغي أن تكون معدلات الزيادة في الجرعة أبطأ في هؤلاء المرضى.</p><p dir="RTL">ينبغي استخدام دواء الريسبيريدون بحذر في مجموعة المرضى هذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة إلى الجرعات المنخفضة، تتوفر أقراص دواء ريسبردال المغلفة بطبقة رقيقة بتركيز 0.5 مجم أو 1 مجم أو 2 مجم ومحلول ريسبردال بتركيز 1 مجم/مل.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة إعطاء الدواء</strong></p><p dir="RTL">للاستخدام عن طريق الفم</p><p>&nbsp;</p><p dir="RTL"><strong><em><u>أقراص دواء ريسبردال المغلفة بطبقة رقيقة</u></em></strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك ابتلاع القرص مع الماء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتواجد الخط الفاصل في القرص لمساعدتك على تقسيمه لنصفين إذا كنت تجد صعوبة في ابتلاعه بأكمله.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong><em><u>محلول ريسبردال الفموي</u></em></strong></p><p dir="RTL">تناول المحلول مع سائل، لكن لا تتناوله مع الشاي الأسود أو الأخضر.</p><p dir="RTL">يعطى المحلول باستخدام محقنة (قطارة). ينبغي استخدام المحقنة لمساعدتك على قياس كمية الدواء المحددة التي تحتاجها.</p><p dir="RTL">يُرجى اتباع هذه الخطوات:</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل الغطاء المانع لعبث الأطفال. ادفع الغطاء اللولبي البلاستيكي لأسفل أثناء لفِّه عكس اتجاه عقارب الساعة (الشكل 1)</p><p>&nbsp;</p><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span lang=EN-GB><span
style='mso-element:field-begin;mso-field-lock:yes'></span></span><span dir=LTR></span><span
dir=LTR></span><span lang=EN-GB dir=LTR><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><img src="data:image/jpeg;base64,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" alt="" width="807" height="709" vspace="0" hspace="0" border="0" style="width:807px;height:709px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB dir=LTR><v:shape id="_x0000_i1028" type="#_x0000_t75" style='width:163.2pt;
 height:122.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB dir=LTR><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:138.6pt;
 height:131.4pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><img src="data:image/jpeg;base64,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" alt="" width="532" height="220" vspace="0" hspace="0" border="0" style="width:532px;height:220px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:138.6pt;
 height:132.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفرغ المحقنة في أي شراب غير كحولي، باستثناء الشاي. اسحب الحلقة العلوية لأسفل</p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أغلق الزجاجة</p><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اشطف السرنجة ببعض الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناولك دواء ريسبردال أكثر مما ينبغي</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استشر طبيبًا في الحال. خذ معك علبة الدواء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تناول جرعة زائدة، قد تشعر بالنعاس أو الإعياء، أو بحركات غير طبيعية في الجسم، ومشكلات عند القيام والمشي، والشعور بالدوخة بسبب انخفاض ضغط الدم، أو التعرض لضربات قلب أو نوبات غير منتظمة.</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة نسيانك تناول دواء ريسبردال</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة نسيانك تناول جرعة، فتناولها فور تذكرها. لكن، إذا كان الوقت قد اقترب من موعد الجرعة التالية، فتجاهل الجرعة الفائتة واستمر في تناول الدواء كالمعتاد. إذا نسيت تناول جرعتين أو أكثر، فاتصل بطبيبك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تتناول جرعة مزدوجة (جرعتين في الوقت نفسه) لتعويض جرعة نسيتها.</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة توقفك عن تناول دواء ريسبردال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينبغي عليك التوقف عن تناول هذا الدواء ما لم يطلب منك الطبيب ذلك. قد تعود الأعراض إلى الظهور مرة أخرى. إذا قرر طبيبك المعالج إيقاف هذا الدواء، يمكنه تقليل الجرعة المخصصة لك تدريجيًا في غضون أيام قليلة.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من عدم إصابة الجميع بها.</p><p>&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا </strong><strong>تعرضت لأي من الآثار الجانبية</strong><strong> </strong><strong>&nbsp;غير الشائعة التالية (قد تؤثر على 1 من كل 100 شخص):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من الخرف وتغيُّر مفاجئ في حالتك العقلية أو ضعف مفاجئ أو تنميل في الوجه أو الذراعين أو الساقين، خاصةً في جانب واحد، أو صعوبة في الكلام ولو لفترة قصيرة من الوقت. قد تكون هذه الأمور من علامات السكتة الدماغية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت لخلل الحركة المتأخر (نفضان أو حركات ارتعاشية لا يمكنك بسببها التحكم في وجهك أو لسانك أو الأجزاء الأخرى من جسمك). أخبر طبيبك على الفور إذا تعرضت لحركات إيقاعية لاإرادية في اللسان والفم والوجه. قد تستلزم الحالة التوقف عن دواء ريسبيردال</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا </strong><strong>تعرضت لأي من الآثار الجانبية</strong><strong> </strong><strong>&nbsp;النادرة التالية (قد تؤثر على 1 من كل 1000 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت للإصابة بجلطات دموية في الأوردة، لا سيما في الأرجل (وتتضمن الأعراض تورم الأرجل والشعور بالألم فيها واحمرارها)، والتي قد تنتقل إلى الرئتين عبر الأوعية الدموية مسببة ألمًا في الصدر وصعوبة في التنفس. إذا لاحظت أي من هذه الأعراض، فاطلب المشورة الطبية على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أُصبت بالحمى أو تصلب العضلات أو التعرق أو انخفاض مستوى الوعي (اضطراب يسمى &quot;المتلازمة الخبيثة للدواء المضاد للذهان&quot;). وقد يلزم توفير العلاج الطبي الفوري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت ذكرًا وتعاني من الانتصاب لفترات طويلة أو الانتصاب المؤلم. يسمى هذا القُسَاح. وقد يلزم توفير العلاج الطبي الفوري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت إلى رد فعل تحسسي حاد مصحوب بالإصابة بالحمى، أو حدوث تورم في الفم أو الوجه أو الشفاه أو اللسان، أو الإصابة بضيق النفس، أو الإصابة بالحكة، أو الإصابة بالطفح الجلدي أو حدوث انخفاض في ضغط الدم.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد تظهر الآثار الجانبية الأخرى التالية أيضًا:</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا (</strong><strong>قد تؤثر على أكثر من 1 من كل 10 أشخاص):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم أو الاستغراق فيه</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباركنسونية: قد تتضمن هذه الحالة: بطء الحركة أو ضعفًا فيها، والإحساس بتصلب العضلات أو تضامها (تجعل الحركات متشنجة)، وأحيانًا حتى الإحساس &quot;بتجمد&quot; في الحركة ثم البدء ثانية. تتضمن العلامات الأخرى لداء باركنسون البطء في تبديل خطوات المشي و/أو الرعشة في وقت الاسترخاء و/أو تزايد اللعاب و/أو سيلان اللعاب من الفم، وفقدان التعبيرات على الوجه</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس أو قلة الانتباه</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية شائعة (</strong><strong>قد تؤثر على 1 من كل 10 أشخاص):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي، التهاب الصدر (التهاب الشعب الهوائية)، أعراض نزلات البرد، التهاب الجيوب الأنفية المعدي، التهاب المسالك البولية، التهاب الأذن، الشعور بأنك مصاب بالأنفلونزا</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور مستويات مرتفعة من هرمون يسمى &quot;البرولاكتين&quot; في اختبار الدم (الذي قد يؤدي أو لا يؤدي إلى ظهور الأعراض). تظهر أعراض ارتفاع البرولاكتين بشكل غير شائع في الرجال وقد تتضمن حدوث تورم في الصدر أو صعوبة في حدوث الانتصاب أو المحافظة عليه أو انخفاض الرغبة الجنسية أو حتى حدوث خلل في الوظيفة الجنسية. أما في النساء، فقد تتضمن الأعراض وجود ألم في الثدي أو حدوث تسرب الحليب من الثديين أو انقطاع الطمث الشهري أو غيرها من المشكلات المتعلقة بالدورة أو مشكلات الخصوبة</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن، زيادة الشهية، انخفاض الشهية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم، الانفعالية، الاكتئاب، القلق، الارتباك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل التوتر العضلى: عبارة عن حالة مرضية مصحوبة بانقباض لاإرادي بطيء أو مستمر في العضلات. في حين أن خلل التوتر يمكن أن يصيب أي جزء من الجسم (وقد يؤدي إلى خلل توتر وضعى)، غالبًا ما يؤثر هذا المرض على عضلات الوجه مثل حدوث حركات غير طبيعية في العينين أو الفم أو اللسان أو الفك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الحركة: عبارة عن حالة مرضية مصحوبة بحركات لاإرادية في العضلات، وقد تتضمن حركات متكررة أو حركات تشنجية أو حركات توجع من الألم، أو نفضان</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف (الارتعاش)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية الضبابية أو التهاب العينين أو &quot;العين القرنفلية&quot;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب، ارتفاع ضغط الدم، ضيق التنفس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق، السعال، النزيف الأنفي، انسداد الأنف</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن، عدم الشعور بالارتياح في البطن، القيء، الغثيان، الإمساك، الإسهال، عسر الهضم، جفاف الفم، ألم الأسنان</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح، احمرار الجلد</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية، وجع العظام أو العضلات، ألم العمود الفقري، ألم المفاصل</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلس البول (عدم السيطرة عليه)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجسم أو الذراعين أو الأرجل، الحمى، ألم الصدر، الضعف، الإجهاد (الإعياء)، الألم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (</strong><strong>قد تؤثر على 1 من كل 100 شخص):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القنوات التنفسية، التهاب المثانة، التهاب العينين، التهاب اللوزتين، العدوى الفطرية في الأظافر، التهاب الجلد، التهاب محصور في منطقة واحدة من الجلد أو جزء من الجسم، عدوى فيروسية، التهاب الجلد الناجم عن حشرات السوس (العث)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانخفاض في نوع كرات الدم البيضاء التي تساعد على حمايتك من العدوى، انخفاض عدد كرات الدم البيضاء، الانخفاض في الصفائح الدموية (خلايا الدم التي تساعد على توقف النزيف)، الأنيميا، الانخفاض في كرات الدم الحمراء، الزيادة في اليوزينيات (نوع من كرات الدم البيضاء) في دمك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد الفعل التحسسي</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكري أو تفاقم السكري، ارتفاع نسبة السكر في الدم، التناول المفرط للماء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن وفقدان الشهية الناتج عن سوء التغذية وانخفاض وزن الجسم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تزايد نسبة الكوليسترول في دمك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المزاج المتهيج (الهوس)، الارتباك، انخفاض الدافع الجنسي، العصبية، الكوابيس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الاستجابة إلى المنبهات، فقدان الوعي، انخفاض مستوى الوعي</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاختلاج (النوبات)، الإغماء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرغبة المستمرة في تحريك أجزاء جسمك، اضطراب التوازن، التناسق غير المنتظم، الشعور بالدوخة عند الوقوف، حدوث اضطراب في الانتباه، مشكلات في التحدث، فقدان مذاق الأطعمة أو يصبح طعمها غير طبيعي، انخفاض إحساس الجلد بالألم واللمس، الإحساس بالتنميل أو الوخز أو التخدير في الجلد</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية العالية للعينين تجاه الضوء، جفاف العينين، تزايد الدموع، احمرار العينين</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بعدم الاتزان (دوار) أو وجود طنين في الأذنين أو ألم في الأذن</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجفان الأذيني (عدم انتظام ضربات القلب)، انقطاع التوصيل بين الأجزاء العلوية والسفلية للقلب، عدم انتظام التوصيل الكهربي للقلب، إطالة فترة كيو تي في القلب، بطء معدل ضربات القلب، عدم انتظام التتبع الكهربي للقلب (مخطط كهربية القلب أو ECG)، الشعور بانتفاضة أو ضربات عنيفة في صدرك (خفقان)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، انخفاض ضغط الدم عند القيام (وبناءً على ذلك، قد يشعر بعض الأشخاص الذين يتناولون دواء ريسبردال بالإغماء أو الدوخة أو قد يفقدون وعيهم عند القيام أو الجلوس فجأة)، الاحمرار</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي الناتج عن استنشاق رائحة الطعام، احتقان الرئة، احتقان القنوات التنفسية، أصوات الفرقعة التي تصدرها الرئة عند التنفس، الأزيز، اضطراب الصوت، اضطراب القناة التنفسية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة أو الالتهاب المعوي، سلس البراز، البراز الصلب للغاية، صعوبة البلع، الإخراج المفرط للغازات أو الرياح</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (أو &quot;الحمى القراصية&quot;)، الحكة، تساقط الشعر، تثخن الجلد، الإكزيما، جفاف الجلد، تبدل لون الجلد، حب الشباب، التقشير، حك فروة الرأس أو الجلد، تهيج الجلد، الآفة الجلدية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الكرياتين فسفوكيناز (CPK) في الدم، وهو إنزيم يخرج أحيانًا مع انهيار العضلات</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وضعيه غير طبيعيه للجسد، تصلب المفاصل، تورم المفاصل، ضعف العضلات، ألم في الرقبة</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التبول المتكرر، عدم القدرة على التبول، ألم عند التبول</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل وظيفي في الانتصاب، اضطراب في القذف</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف الطمث الشهري أو انقطاع الطمث الشهري أو غيرها من المشكلات المتعلقة بالدورة لديك (بالنسبة إلى الإناث)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروز الصدر في الرجال، تسرب اللبن من الثديين، خلل في الوظيفة الجنسية، ألم في الثدي، وجع في الثدي، الإفرازات المهبلية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الفم أو العينين أو الشفتين</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة، ارتفاع في درجة حرارة الجسم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في طريقة مشيتك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالظمأ، الشعور بالتعب، وجع في الصدر، الشعور &quot;بمزاج متقلب&quot;، عدم الراحة</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيم الكبد &quot;ترنساميناز&quot; في دمك، زيادة إنزيم الكبد &quot;ناقل الغاما-غلوتاميل (GGT)&quot; في دمك، زيادة إنزيمات الكبد في دمك</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم إجرائي.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (</strong><strong>قد تؤثر على 1 من كل 1000 شخص):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إفراز غير ملائم للهرمون الذي يتحكم في كمية البول</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشي أثناء النوم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأكل المرتبطة بالنوم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسبة السكر في البول، انخفاض نسبة السكر في الدم، ارتفاع نسبة الدهون الثلاثية في الدم (الشحم)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فتور العاطفة، عدم القدرة على الوصول إلى هزة الجماع</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الحركة أو الاستجابة أثناء اليقظة (الجامود)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الأوعية الدموية الموجودة في الدماغ</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغيبوبة الناتجة عن عدم انضباط معدلات السكري</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اهتزاز الرأس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلوكوما (ارتفاع ضغط العين)، مشكلات تصاحب حركة عينيك، دوران العين، تقشير حواف جفن العين</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات العينين أثناء إجراء جراحة المياه البيضاء. أثناء إجراء جراحة المياه البيضاء، يمكن أن تحدث متلازمة القزحية الرخوة أثناء الجراحة (IFIS) إذا تناولت أو كنت قد تناولت دواء ريسبردال. إذا كنت بحاجة إلى إجراء جراحة المياه البيضاء، فتأكد من إخبار طبيب العيون المعالج لك بأنك تتناول أو كنت قد تناولت هذا الدواء.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حاد في أعداد نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإفراط في تناول الماء بشكل خطير</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس أثناء النوم (انقطاع النفس أثناء النوم)، التنفس السريع والتنفس البطيء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس، انسداد في الأمعاء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللسان، تشقق الشفاه، طفح على الجلد مرتبط بالدواء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشرة الرأس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انهيار الألياف العضلية وألم في العضلات (انحلال الربيدات)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأخر الطمث الشهري، تضخم الغدد الموجودة في الثديين، تضخم الثدي، إفرازات من الثديين</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الأنسولين (هرمون يتحكم في مستويات السكر في الدم) في الدم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب الجلد</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة حرارة الجسم، برودة في الذراعين والساقين</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض إيقاف الدواء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين (اليرقان).</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جدًا (</strong><strong>قد تؤثر على 1 من كل 10000&nbsp;شخص):</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضاعفات المهددة للحياة الناتجة عن عدم انتظام معدلات السكري</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد الفعل التحسسي الحاد مع تورم في الحلق يؤدي إلى صعوبة التنفس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وجود حركة في العضلات بما يسبب انسدادًا في الأمعاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرار هذه الآثار من البيانات المتاحة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد أو مهدد للحياة مصحوب ببثور وتقشر جلدي قد يبدأ في الفم وحوله والأنف والعينين والأعضاء التناسلية وينتشر إلى مناطق أخرى من الجسم (متلازمة ستيفنز جونسون أو تقشر الأنسجة المتموتة البشروية التسممي).</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">تظهر الآثار الجانبية التالية مع استخدام دواء آخر يسمى الباليبيريدون الذي له خواص الريسبيريدون نفسها، لذلك من المتوقع أيضًا ظهور تلك الآثار الجانبية مع دواء ريسبردال وفق ما يلي: تسارع ضربات القلب عند الوقوف.</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية إضافية في الأطفال والمراهقين</strong></p><p dir="RTL">بوجه عام، يتوقع أن تتشابه الآثار الجانبية التي تظهر في الأطفال مع تلك التي تظهر في المراهقين.</p><p dir="RTL">تم الإبلاغ عن ظهور الآثار الجانبية التالية في الغالب أكثر في الأطفال والمراهقين (من 5 سنوات إلى 17&nbsp;سنة) عن البالغين: الشعور بالنعاس، أو درجة يقظة قليلة، والإجهاد (الإعياء) والصداع والشهية المفتوحة والقيء وأعراض نزلات البرد واحتقان الأنف وألم في البطن والشعور بالدوخة والسعال والحمى والارتجاف (الارتعاش) والإسهال وسلس (عدم السيطرة على) البول.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت عليك أي آثار جانبية، فاستشر طبيبك أو الصيدلي. ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية يمكن أن تساعد على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المحدد على شريط الدواء أو العبوة الكرتونية الخارجية أو زجاجة الدواء. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">يجب عدم تخزينه في درجة حرارة أعلى من 30&deg; درجة مئوية.</p><p>&nbsp;</p><p dir="RTL"><strong>أقراص دواء ريسبردال المغلفة بطبقة رقيقة</strong></p><p dir="RTL">أشرطة أقراص الدواء: تُخزّن في العبوة الأصلية لحمايتها من الضوء.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>محلول ريسبردال الفموي</strong></p><p>&nbsp;</p><p dir="RTL">يُمنع الحفظ في الثلاجة أو تجميده.</p><p>&nbsp;</p><p dir="RTL">بمجرد فتح زجاجة الدواء، يجب التخلص من أي كمية غير مستخدمة من محلول ريسبردال الفموي بعد مضي 3 أشهر.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي (على سبيل المثال في المرحاض أو المغسلة). اسأل &nbsp;في الصيدلية عن كيفية التخلص من الأدوية التي لم تعد بحاجة إلى استخدامها. ستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي يحتويه دواء ريسبردال</strong></p><p dir="RTL">المادة الفعالة به هي الريسبيريدون</p><p>&nbsp;</p><p dir="RTL">يحتوي كل قرص من أقراص دواء ريسبردال المغلفة بطبقة رقيقة على كمية من مادة الريسبيريدون تبلغ 1 مجم أو 2 مجم أو 3 مجم أو 4 مجم.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">أقراص ريسبردال بتركيز 1&nbsp;مجم المغلفة بطبقة رقيقة:</p><p dir="RTL"><em><u>مكونات الأقراص الأساسية:</u></em> لاكتوز أحادي الهيدرات ونشا الذرة وسيلولوز بلوري مِكرويّ (E460) وهيبروميلوز (E464) وستيارات الماغنيسيوم والسيليكا الغروانية اللامائية و كبريتات لوريل &nbsp;الصوديوم.</p><p dir="RTL"><em><u>طبقة التغليف</u></em>: هيبروميلوز (E464) وغليكول بروبيلين (E490).</p><p>&nbsp;</p><p dir="RTL">أقراص ريسبردال بتركيز 2&nbsp;مجم المغلفة بطبقة رقيقة:</p><p dir="RTL"><em><u>مكونات الأقراص الأساسية:</u></em> لاكتوز أحادي الهيدرات ونشا الذرة وسيلولوز بلوري مِكرويّ (E460) وهيبروميلوز (E464) وستيارات الماغنيسيوم والسيليكا الغروانية اللامائية و كبريتات لوريل &nbsp;الصوديوم.</p><p dir="RTL"><em><u>طبقة التغليف</u></em>: هيبروميلوز (E464) وغليكول بروبيلين (E490) وثاني أكسيد التيتانيوم (E171) والتلك (E553B) وصبغة كبريتات الألمونيوم الصفراء البرتقالية (صفراء مثل لون غروب الشمس) E110.</p><p>&nbsp;</p><p dir="RTL">أقراص ريسبردال بتركيز 3&nbsp;مجم المغلفة بطبقة رقيقة:</p><p dir="RTL"><em><u>مكونات الأقراص الأساسية:</u></em> لاكتوز أحادي الهيدرات ونشا الذرة وسيليلوز بلوري مِكرويّ (E460) وهيبروميلوز (E464 وستيارات الماغنيسيوم والسيليكا الغروانية اللامائية وكبريتات لوريل الصوديوم.</p><p dir="RTL"><em><u>طبقة التغليف:</u></em> هيبروميلوز (E464) وغليكول بروبيلين (E490) وثاني أكسيد التيتانيوم (E171) والتلك (E553B) وكينولين الأصفر&nbsp;(E104).</p><p>&nbsp;</p><p dir="RTL">أقراص ريسبردال بتركيز 4&nbsp;مجم المغلفة بطبقة رقيقة:</p><p dir="RTL"><em><u>مكونات الأقراص الأساسية:</u></em> لاكتوز أحادي الهيدرات ونشا الذرة وسيلولوز بلوري مِكرويّ (E460) وهيبروميلوز (E464) وستيارات الماغنيسيوم والسيليكا الغروانية اللامائية و كبريتات لوريل &nbsp;الصوديوم.</p><p dir="RTL"><em><u>طبقة التغليف:</u></em> هيبروميلوز (E464) وغليكول بروبيلين (E490) وثاني أكسيد التيتانيوم (E171) والتلك (E553B) وكينولين الأصفر (E104) وصبغة الألمونيوم ثنائية سلفونات الإنديغوتين (E132).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">يحتوي المللي الواحد من محلول ريسبردال الفموي على 1 مجم من دواء الريسبيريدون.</p><p>&nbsp;</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">حمض الطرطريك(Ph.Eur) &nbsp;وحمض البنزويك وهيدروكسيد الصوديوم والمياه النقية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما شكل دواء ريسبردال وما محتويات العبوة</strong></p><p dir="RTL">تعبأ أقراص دواء ريسبردال المغلفة بطبقة رقيقة في شرائط ورق ألمونيوم أو متعدد كلوريد الفينيل &nbsp;أو بولى ايثيلين منخفض الكثافة &nbsp;أو متعدد كلوريد ليدين الفينيل وزجاجات بولي إيثيلين عالية الكثافة ذات الغطاء اللولبي من البولي بروبيلين.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>أقراص دواء ريسبردال المغلفة بطبقة رقيقة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء الريسبيريدون بتركيز 1 مجم هو أقراص بيضاء اللون مغلفة بطبقة رقيقة تُقسم من النصف بسهولة ومحدبة الوجهين ومستطيلة الشكل بحجم 10.5 مم &times; 5 مم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء الريسبيريدون بتركيز 2 مجم هو أقراص برتقالية اللون مغلفة بطبقة رقيقة تُقسم من النصف بسهولة ومحدبة الوجهين ومستطيلة الشكل بحجم 10.5 مم &times; 5 مم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء الريسبيريدون بتركيز 3 مجم هو أقراص صفراء اللون مغلفة بطبقة رقيقة تُقسم من النصف بسهولة ومحدبة الوجهين ومستطيلة الشكل بحجم 13.5 مم &times; 5 مم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء الريسبيريدون بتركيز 4 مجم هو أقراص خضراء اللون مغلفة بطبقة رقيقة تُقسم من النصف بسهولة ومحدبة الوجهين ومستطيلة الشكل بحجم 15 مم &times; 6.5 مم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">تطبع هذه الرموز على أحد جانبي الأقراص المغلفة بطبقة رقيقة وهي على التوالي:&nbsp; RIS 1 وRIS 2 وRIS 3 وRIS 4. ويمكن طباعة كلمة JANSSEN، بشكل إضافي، على الجانب الآخر.</p><p>&nbsp;</p><p dir="RTL">أحجام العبوة</p><p dir="RTL">تتوافر أقراص ريسبردال المغلفة بطبقة رقيقة بأحجام العبوات التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيز 1 مجم: عبوات بها أشرطة تحتوي على 6 أو 20 أو 50 أو 60 أو 100 قرص وزجاجات تحتوي على 500 قرص</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيز 2&nbsp;مجم: عبوات بها أشرطة تحتوي على 10 أو 20 أو 50 أو 60 أو 100 قرص وزجاجات تحتوي على 500 قرص</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيز 3&nbsp;مجم: عبوات بها أشرطة تحتوي على 20 أو 50 أو 60 أو 100 قرص</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيز 4&nbsp;مجم: عبوات بها أشرطة تحتوي على 10 أو 20 أو 30 أو 50 أو 60 أو 100 قرص</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p><em>&nbsp;</em></p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>المحلول الفموي</strong></p><p dir="RTL">يقدم محلول ريسبردال بتركيز 100 مجم/مل في زجاجة كهرمانية اللون بغطاء مقاوم للأطفال وتحتوي على جرعات 30 مل أو 60 مل أو 100 مل أو 120 مل؛ من سائل صافٍ وعديم اللون. يتم تقديم قطارة للجرعات (جهاز طبي معتمد) أيضًا.</p><p>&nbsp;</p><p dir="RTL">تكون القطارة المقدمة مع الزجاجة بحجم 30 مل أو 60 مل أو 100 مل مدرجةً بالمليجرامات والمليليترات بحجم 0.25 مل كحد أدني و3&nbsp;مل كحد أقصى. تطبع علامات التدرج بقيم تزايدية مقدارها 0.25 مل (تُعادل 0.25 مجم في المحلول الفموي) حتى تصل إلى 3 مل (تُعادل 3 مجم في المحلول الفموي) على هذه القطارة. تكون القطارة المقدمة مع الزجاجة بحجم 120 مل مدرجةً بالمللي جرام والمللي لتر بحجم 0.25 مل كحد أدني و4 مل كحد أقصى. تطبع علامات التدرج بقيم تزايدية مقدارها 0.25 مل (تُعادل 0.25 مجم في المحلول الفموي) حتى تصل إلى 4 مل (تُعادل 4 مجم في المحلول الفموي) على هذه القطارة.</p><p>&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل الرخصة التسويقية</strong></p><p dir="RTL">جانسن سيلاج- إن ڨي انتوربيسويج 15-17 بي-2340 بييرس- بلجيكا</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p dir="RTL"><u>أقراص ريسبردال</u>:</p><p dir="RTL">جانسن-سيلاج اس بي ايه، فيا سي. جانسن ( ال اوه سي. بورجو إس. مايكل)- 04100 لاتينا (ال تى)، إيطاليا</p><p dir="RTL"><u>محلول ريسبردال الفموي</u>:</p><p dir="RTL">&nbsp;جانسن فارماسيوتيكا إن في- ترنهوتسويج- 30- 2340 بيرس- بلجيكا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في 19-أغسطس-2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
RISPERDAL solution 1 mg/ml, oral solution


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
1 ml oral solution contains 1 mg of risperidone.

Excipients with known effect
1 ml oral solution contains 2 mg benzoic acid (E 210).

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution
The oral solution is clear and colourless.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RISPERDAL is indicated for the treatment of schizophrenia.</p><p>&nbsp;</p><p>RISPERDAL is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.</p><p>&nbsp;</p><p>RISPERDAL is indicated for the short‑term treatment (up to 6&nbsp;weeks) of persistent aggression in patients with moderate to severe Alzheimer&rsquo;s dementia unresponsive to non‑pharmacological approaches and when there is a risk of harm to self or others.</p><p>&nbsp;</p><p>RISPERDAL is indicated for the short‑term symptomatic treatment (up to 6&nbsp;weeks) of persistent aggression in conduct disorder in children from the age of 5&nbsp;years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM‑IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Schizophrenia</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Adults</em></p><p>RISPERDAL may be given once daily or twice daily.</p><p>&nbsp;</p><p>Patients should start with 2&nbsp;mg/day risperidone. The dosage may be increased on the second day to 4&nbsp;mg. Subsequently, the dosage can be maintained unchanged, or further individualised, if needed. Most patients will benefit from daily doses between 4 and 6&nbsp;mg. In some patients, a slower titration phase and a lower starting and maintenance dose may be appropriate.</p><p>&nbsp;</p><p>Doses above 10&nbsp;mg/day have not demonstrated superior efficacy to lower doses and may cause increased incidence of extrapyramidal symptoms. Safety of doses above 16&nbsp;mg/day has not been evaluated, and are therefore not recommended.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>A starting dose of 0.5&nbsp;mg twice daily is recommended. This dosage can be individually adjusted with 0.5&nbsp;mg twice daily increments to 1 to 2&nbsp;mg twice daily.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>Risperidone is not recommended for use in children and adolescents below age&nbsp;18 with schizophrenia due to a lack of data on efficacy.</p><p>&nbsp;</p><p><em><u>Manic episodes in bipolar disorder</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Adults</em></p><p>RISPERDAL should be administered on a once daily schedule, starting with 2&nbsp;mg risperidone. Dosage adjustments, if indicated, should occur at intervals of not less than 24&nbsp;hours and in dosage increments of 1&nbsp;mg per day. Risperidone can be administered in flexible doses over a range of 1 to 6&nbsp;mg per day to optimise each patient&rsquo;s level of efficacy and tolerability. Daily doses over 6&nbsp;mg risperidone have not been investigated in patients with manic episodes.</p><p>&nbsp;</p><p>As with all symptomatic treatments, the continued use of RISPERDAL must be evaluated and justified on an ongoing basis.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>A starting dose of 0.5&nbsp;mg twice daily is recommended. This dosage can be individually adjusted with 0.5&nbsp;mg twice daily increments to 1 to 2&nbsp;mg twice daily. Since clinical experience in elderly is limited, caution should be exercised.</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>Risperidone is not recommended for use in children and adolescents below age&nbsp;18 with bipolar mania due to a lack of data on efficacy.</p><p><strong>&nbsp;</strong></p><p><em><u>Persistent aggression in patients with moderate to severe Alzheimer&rsquo;s dementia</u></em></p><p><em><u>&nbsp;</u></em></p><p>A starting dose of 0.25&nbsp;mg of the oral solution twice daily is recommended. The oral solution is the recommended pharmaceutical form to administer 0.25&nbsp;mg. This dosage can be individually adjusted by increments of 0.25&nbsp;mg twice daily, not more frequently than every other day, if needed. The optimum dose is 0.5&nbsp;mg twice daily for most patients. Some patients, however, may benefit from doses up to 1&nbsp;mg twice daily.</p><p>&nbsp;</p><p>RISPERDAL should not be used more than 6&nbsp;weeks in patients with persistent aggression in Alzheimer&rsquo;s dementia. During treatment, patients must be evaluated frequently and regularly, and the need for continuing treatment reassessed.</p><p>&nbsp;</p><p><em><u>Conduct disorder</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Children and adolescents from 5 to 18&nbsp;years of age</em></p><p>For subjects &sup3;&nbsp;50&nbsp;kg, a starting dose of 0.5&nbsp;mg once daily is recommended. This dosage can be individually adjusted by increments of 0.5&nbsp;mg once daily not more frequently than every other day, if needed. The optimum dose is 1&nbsp;mg once daily for most patients. Some patients, however, may benefit from 0.5&nbsp;mg once daily while others may require 1.5&nbsp;mg once daily. For subjects &lt;&nbsp;50&nbsp;kg, a starting dose of 0.25&nbsp;mg of the oral solution once daily is recommended. The oral solution is the recommended pharmaceutical form to administer 0.25&nbsp;mg. This dosage can be individually adjusted by increments of 0.25&nbsp;mg once daily not more frequently than every other day, if needed. The optimum dose is 0.5&nbsp;mg once daily for most patients. Some patients, however, may benefit from 0.25&nbsp;mg once daily while others may require 0.75&nbsp;mg of the oral solution once daily. The oral solution is the recommended pharmaceutical form to administer 0.75&nbsp;mg.</p><p>&nbsp;</p><p>As with all symptomatic treatments, the continued use of RISPERDAL must be evaluated and justified on an ongoing basis.</p><p>&nbsp;</p><p>RISPERDAL is not recommended in children less than 5&nbsp;years of age, as there is no experience in children less than 5&nbsp;years of age with this disorder.</p><p>&nbsp;</p><p><em><u>Renal and hepatic impairment</u></em></p><p><em><u>&nbsp;</u></em></p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than in adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of risperidone.</p><p>&nbsp;</p><p>Irrespective of the indication, starting and consecutive dosing should be halved, and dose titration should be slower for patients with renal or hepatic impairment.</p><p>&nbsp;</p><p>RISPERDAL should be used with caution in these groups of patients.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>RISPERDAL is for oral use. Food does not affect the absorption of RISPERDAL.</p><p>&nbsp;</p><p>Upon discontinuation, gradual withdrawal is advised. Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have very rarely been described after abrupt cessation of high doses of antipsychotic medicines (see section 4.8). Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported.</p><p>&nbsp;</p><p><em>Switching from other antipsychotics</em></p><p>When medically appropriate, gradual discontinuation of the previous treatment while RISPERDAL therapy is initiated is recommended. Also, if medically appropriate, when switching patients from depot antipsychotics, initiate RISPERDAL therapy in place of the next scheduled injection. The need for continuing existing anti‑Parkinson medicines should be re‑evaluated periodically.</p><p>&nbsp;</p><p>RISPERDAL oral solution is incompatible with most types of tea including black tea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RISPERDAL oral solution must not be used in case of
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Elderly patients with dementia</u></p><p><u>&nbsp;</u></p><p><em>Total mortality</em></p><p>In a meta‑analysis of 17&nbsp;controlled trials of atypical antipsychotics, including RISPERDAL, elderly patients with dementia treated with atypical antipsychotics have an increased mortality compared to placebo. In placebo‑controlled trials with oral RISPERDAL in this population, the incidence of mortality was 4.0% for RISPERDAL‑treated patients compared to 3.1% for placebo‑treated patients. The odds ratio (95% exact confidence interval) was 1.21 (0.7; 2.1). The mean age (range) of patients who died was 86&nbsp;years (range 67‑100). Data from two large observational studies showed that elderly people with dementia who are treated with conventional antipsychotics are also at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</p><p>&nbsp;</p><p><em>Concomitant use with furosemide</em></p><p>In the RISPERDAL placebo‑controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone (7.3%; mean age 89&nbsp;years, range 75‑97) when compared to patients treated with risperidone alone (3.1%; mean age 84&nbsp;years, range 70‑96) or furosemide alone (4.1%; mean age 80&nbsp;years, range 67‑90). The increase in mortality in patients treated with furosemide plus risperidone was observed in two of the four clinical trials. Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.</p><p>No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or co‑treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be carefully avoided in elderly patients with dementia.</p><p><u>&nbsp;</u></p><p><u>Cerebrovascular adverse events (CVAE)</u></p><p>&nbsp;</p><p>An approximately 3‑fold increased risk of cerebrovascular adverse events have been seen in randomised placebo‑controlled clinical trials in the dementia population with some atypical antipsychotics. The pooled data from six placebo‑controlled studies with RISPERDAL in mainly elderly patients (&gt;&nbsp;65&nbsp;years of age) with dementia showed that CVAEs (serious and non‑serious, combined) occurred in 3.3% (33/1,009) of patients treated with risperidone and 1.2% (8/712) of patients treated with placebo. The odds ratio (95% exact confidence interval) was 2.96 (1.34; 7.50). The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. RISPERDAL should be used with caution in patients with risk factors for stroke.</p><p>&nbsp;</p><p>The risk of CVAEs was significantly higher in patients with mixed or vascular type of dementia when compared to Alzheimer&rsquo;s dementia. Therefore, patients with other types of dementias than Alzheimer&rsquo;s should not be treated with risperidone.</p><p>&nbsp;</p><p>Physicians are advised to assess the risks and benefits of the use of RISPERDAL in elderly patients with dementia, taking into account risk predictors for stroke in the individual patient. Patients/caregivers should be cautioned to immediately report signs and symptoms of potential CVAEs such as sudden weakness or numbness in the face, arms or legs, and speech or vision problems. All treatment options should be considered without delay, including discontinuation of risperidone.</p><p>&nbsp;</p><p>RISPERDAL should only be used short term for persistent aggression in patients with moderate to severe Alzheimer&rsquo;s dementia to supplement non‑pharmacological approaches which have had limited or no efficacy and when there is potential risk of harm to self or others.</p><p>&nbsp;</p><p>Patients should be reassessed regularly, and the need for continuing treatment reassessed.</p><p>&nbsp;</p><p><u>Orthostatic hypotension</u></p><p>&nbsp;</p><p>Due to the alpha‑blocking activity of risperidone, (orthostatic) hypotension can occur, especially during the initial dose‑titration period. Clinically significant hypotension has been observed post‑marketing with concomitant use of risperidone and antihypertensive treatment. RISPERDAL should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction, conduction abnormalities, dehydration, hypovolaemia, or cerebrovascular disease), and the dosage should be gradually titrated as recommended (see section 4.2). A dose reduction should be considered if hypotension occurs.</p><p>&nbsp;</p><p><u>Leucopenia, neutropenia, and agranulocytosis</u></p><p>&nbsp;</p><p>Events of leucopenia, neutropenia and agranulocytosis have been reported with antipsychotic agents, including RISPERDAL. Agranulocytosis has been reported very rarely (&lt;&nbsp;1/10,000&nbsp;patients) during post‑marketing surveillance.</p><p>&nbsp;</p><p>Patients with a history of a clinically significant low white blood cell count (WBC) or a drug‑induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of RISPERDAL should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p><p>&nbsp;</p><p>Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt;&nbsp;1&nbsp;&times;&nbsp;10<sup>9</sup>/L) should discontinue RISPERDAL and have their WBC followed until recovery.</p><p><u>&nbsp;</u></p><p><u>Tardive dyskinesia/extrapyramidal symptoms (TD/EPS)</u></p><p>&nbsp;</p><p>Medicines with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical involuntary movements, predominantly of the tongue and/or face. The onset of extrapyramidal symptoms is a risk factor for tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics should be considered.</p><p>&nbsp;</p><p>Caution is warranted in patients receiving both psychostimulants (e.g. methylphenidate) and risperidone concomitantly, as extrapyramidal symptoms could emerge when adjusting one or both medications. Gradual withdrawal of stimulant treatment is recommended (see section 4.5).</p><p><strong><em>&nbsp;</em></strong></p><p><u>Neuroleptic malignant syndrome (NMS)</u></p><p>&nbsp;</p><p>Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels has been reported to occur with antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. In this event, all antipsychotics, including RISPERDAL, should be discontinued.</p><p>&nbsp;</p><p><u>Parkinson&rsquo;s disease and dementia with Lewy bodies</u></p><p>&nbsp;</p><p>Physicians should weigh the risks versus the benefits when prescribing antipsychotics, including RISPERDAL, to patients with Parkinson&rsquo;s Disease or Dementia with Lewy Bodies (DLB). Parkinson&rsquo;s Disease may worsen with risperidone. Both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medicinal products; these patients were excluded from clinical trials. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>&nbsp;</p><p>Hyperglycaemia, diabetes mellitus, and exacerbation of pre‑existing diabetes have been reported during treatment with RISPERDAL. In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Association with ketoacidosis has been reported very rarely and rarely with diabetic coma. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with any atypical antipsychotic, including RISPERDAL, should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><u>Weight gain</u></p><p><u>&nbsp;</u></p><p>Significant weight gain has been reported with RISPERDAL use. Weight should be monitored regularly.</p><p>&nbsp;</p><p><u>Hyperprolactinaemia</u></p><p>&nbsp;</p><p>Hyperprolactinaemia is a common side effect of treatment with RISPERDAL. Evaluation of the prolactin plasma level is recommended in patients with evidence of possible prolactin‑related side effects (e.g., gynaecomastia, menstrual disorders, anovulation, fertility disorder, decreased libido, erectile dysfunction, and galactorrhoea).</p><p>&nbsp;</p><p>Tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history. RISPERDAL should be used with caution in patients with pre‑existing hyperprolactinaemia and in patients with possible prolactin‑dependent tumours.</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p>&nbsp;</p><p>QT prolongation has very rarely been reported post‑marketing. As with other antipsychotics, caution should be exercised when risperidone is prescribed in patients with known cardiovascular disease, family history of QT prolongation, bradycardia, or electrolyte disturbances (hypokalaemia, hypomagnesaemia), as it may increase the risk of arrhythmogenic effects, and in concomitant use with medicines known to prolong the QT interval.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>&nbsp;</p><p>RISPERDAL should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Priapism</u></p><p>&nbsp;</p><p>Priapism may occur with RISPERDAL treatment due to its alpha‑adrenergic blocking effects.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Body temperature regulation</u></p><p>&nbsp;</p><p>Disruption of the body&rsquo;s ability to reduce core body temperature has been attributed to antipsychotic medicines. Appropriate care is advised when prescribing RISPERDAL to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant treatment with anticholinergic activity, or being subject to dehydration.</p><p>&nbsp;</p><p><u>Antiemetic effect</u></p><p><u>&nbsp;</u></p><p>An antiemetic effect was observed in preclinical studies with risperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicines or of conditions such as intestinal obstruction, Reye&rsquo;s syndrome, and brain tumour.</p><p><u>&nbsp;</u></p><p><u>Renal and hepatic impairment</u></p><p>&nbsp;</p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of risperidone (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Venous thromboembolism</u></p><p>&nbsp;</p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with RISPERDAL and preventative measures undertaken.</p><p>&nbsp;</p><p><u>Intraoperative floppy iris syndrome</u></p><p><u>&nbsp;</u></p><p>Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients treated with medicines with alpha1a‑adrenergic antagonist effect, including RISPERDAL (see section 4.8).</p><p>&nbsp;</p><p>IFIS may increase the risk of eye complications during and after the operation. Current or past use of medicines with alpha1a‑adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery. The potential benefit of stopping alpha1‑blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Before risperidone is prescribed to a child or adolescent with conduct disorder they should be fully assessed for physical and social causes of the aggressive behaviour such as pain or inappropriate environmental demands.</p><p>&nbsp;</p><p>The sedative effect of risperidone should be closely monitored in this population because of possible consequences on learning ability. A change in the time of administration of risperidone could improve the impact of the sedation on attention faculties of children and adolescents.</p><p>&nbsp;</p><p>Risperidone was associated with mean increases in body weight and body mass index (BMI). Baseline weight measurement prior to treatment and regular weight monitoring are recommended. Changes in height in the long‑term open‑label extension studies were within expected age‑appropriate norms. The effect of long‑term risperidone treatment on sexual maturation and height has not been adequately studied.</p><p>&nbsp;</p><p>Because of the potential effects of prolonged hyperprolactinaemia on growth and sexual maturation in children and adolescents, regular clinical evaluation of endocrinological status should be considered, including measurements of height, weight, sexual maturation, monitoring of menstrual functioning, and other potential prolactin‑related effects.</p><p>&nbsp;</p><p>Results from a small post‑marketing observational study showed that risperidone‑exposed subjects between the ages of 8‑16&nbsp;years were on average approximately 3.0 to 4.8&nbsp;cm taller than those who received other atypical antipsychotic medications. This study was not adequate to determine whether exposure to risperidone had any impact on final adult height, or whether the result was due to a direct effect of risperidone on bone growth, or the effect of the underlying disease itself on bone growth, or the result of better control of the underlying disease with resulting increase in linear growth.</p><p>&nbsp;</p><p>During treatment with risperidone regular examination for extrapyramidal symptoms and other movement disorders should also be conducted.</p><p>&nbsp;</p><p>For specific posology recommendations in children and adolescents see section 4.2.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Excipients</u></p><p>&nbsp;</p><p>RISPERDAL oral solution contains benzoic acid (E 210). Increase in bilirubinaemia following its displacement from albumin may increase neonatal jaundice which may develop into kernicterus (non‑conjugated bilirubin deposits in the brain tissue).</p><p>&nbsp;</p><p>RISPERDAL oral solution contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say, essentially &lsquo;sodium free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic‑related interactions</u></p><p>&nbsp;</p><p><em>Drugs known to prolong the QT interval</em></p><p>As with other antipsychotics, caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval, such as antiarrhythmics (e.g., quinidine, dysopiramide, procainamide, propafenone, amiodarone, sotalol), tricyclic antidepressants (i.e., amitriptyline), tetracyclic antidepressants (i.e., maprotiline), some antihistamines, other antipsychotics, some antimalarials (i.e., quinine and mefloquine), and with medicines causing electrolyte imbalance (hypokalaemia, hypomagnesaemia), bradycardia, or those which inhibit the hepatic metabolism of risperidone. This list is indicative and not exhaustive.</p><p>&nbsp;</p><p><em>Centrally‑acting drugs and alcohol</em></p><p>Risperidone should be used with caution in combination with other centrally‑acting substances notably including alcohol, opiates, antihistamines and benzodiazepines due to the increased risk of sedation.</p><p>&nbsp;</p><p><em>Levodopa and dopamine agonists</em></p><p>RISPERDAL may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end‑stage Parkinson&rsquo;s disease, the lowest effective dose of each treatment should be prescribed.</p><p>&nbsp;</p><p><em>Drugs with hypotensive effect</em></p><p>Clinically significant hypotension has been observed post‑marketing with concomitant use of risperidone and antihypertensive treatment.</p><p><em>&nbsp;</em></p><p><em>Psychostimulants</em></p><p>The combined use of psychostimulants (e.g. methylphenidate) with risperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).</p><p>&nbsp;</p><p><em>Paliperidone</em></p><p>Concomitant use of oral RISPERDAL with paliperidone is not recommended as paliperidone is the active metabolite of risperidone and the combination of the two may lead to additive active antipsychotic fraction exposure.</p><p>&nbsp;</p><p><u>Pharmacokinetic‑related interactions</u></p><p><u>&nbsp;</u></p><p>Food does not affect the absorption of RISPERDAL.</p><p>&nbsp;</p><p>Risperidone is mainly metabolised through CYP2D6, and to a lesser extent through CYP3A4. Both risperidone and its active metabolite 9‑hydroxy‑risperidone are substrates of P‑glycoprotein (P‑gp). Substances that modify CYP2D6 activity, or substances strongly inhibiting or inducing CYP3A4 and/or P‑gp activity, may influence the pharmacokinetics of the risperidone active antipsychotic fraction.</p><p>&nbsp;</p><p><em>Strong CYP2D6 inhibitors</em></p><p>Co‑administration of RISPERDAL with a strong CYP2D6 inhibitor may increase the plasma concentrations of risperidone, but less so of the active antipsychotic fraction. Higher doses of a strong CYP2D6 inhibitor may elevate concentrations of the risperidone active antipsychotic fraction (e.g., paroxetine, see below). It is expected that other CYP2D6 inhibitors, such as quinidine, may affect the plasma concentrations of risperidone in a similar way. When concomitant paroxetine, quinidine, or another strong CYP2D6 inhibitor, especially at higher doses, is initiated or discontinued, the physician should re‑evaluate the dosing of RISPERDAL.</p><p>&nbsp;</p><p><em>CYP3A4 and/or P‑gp inhibitors</em></p><p>Co‑administration of RISPERDAL with a strong CYP3A4 and/or P‑gp inhibitor may substantially elevate plasma concentrations of the risperidone active antipsychotic fraction. When concomitant itraconazole or another strong CYP3A4 and/or P‑gp inhibitor is initiated or discontinued, the physician should re‑evaluate the dosing of RISPERDAL.</p><p>&nbsp;</p><p><em>CYP3A4 and/or P‑gp inducers</em></p><p>Co‑administration of RISPERDAL with a strong CYP3A4 and/or P‑gp inducer may decrease the plasma concentrations of the risperidone active antipsychotic fraction. When concomitant carbamazepine or another strong CYP3A4 and/or P‑gp inducer is initiated or discontinued, the physician should re‑evaluate the dosing of RISPERDAL. CYP3A4 inducers exert their effect in a time‑dependent manner, and may take at least 2&nbsp;weeks to reach maximal effect after introduction. Conversely, on discontinuation, CYP3A4 induction may take at least 2&nbsp;weeks to decline.</p><p>&nbsp;</p><p><em>Highly protein‑bound drugs</em></p><p>When RISPERDAL is taken together with highly protein‑bound drugs, there is no clinically relevant displacement of either drug from the plasma proteins.</p><p>&nbsp;</p><p>When using concomitant medication, the corresponding label should be consulted for information on the route of metabolism and the possible need to adjust dosage.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Interaction studies have only been performed in adults. The relevance of the results from these studies in paediatric patients is unknown.</p><p>&nbsp;</p><p>The combined use of psychostimulants (e.g., methylphenidate) with RISPERDAL in children and adolescents did not alter the pharmacokinetics and efficacy of RISPERDAL.</p><p>&nbsp;</p><p><u>Examples</u></p><p><u>&nbsp;</u></p><p>Examples of drugs that may potentially interact or that were shown not to interact with risperidone are listed below:</p><p>&nbsp;</p><p><u>Effect of other medicinal products on the pharmacokinetics of risperidone</u></p><p>&nbsp;</p><p>Antibacterials:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythromycin, a moderate CYP3A4 inhibitor and P‑gp inhibitor, does not change the pharmacokinetics of risperidone and the active antipsychotic fraction.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, a strong CYP3A4 inducer and a P‑gp inducer, decreased the plasma concentrations of the active antipsychotic fraction.</p><p>Anticholinesterases:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Donepezil and galantamine, both CYP2D6 and CYP3A4 substrates, do not show a clinically relevant effect on the pharmacokinetics of risperidone and the active antipsychotic fraction.</p><p>Antiepileptics:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine, a strong CYP3A4 inducer and a P‑gp inducer, has been shown to decrease the plasma concentrations of the active antipsychotic fraction of risperidone. Similar effects may be observed with e.g., phenytoin and phenobarbital which also induce CYP3A4 hepatic enzyme, as well as P‑glycoprotein.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topiramate modestly reduced the bioavailability of risperidone, but not that of the active antipsychotic fraction. Therefore, this interaction is unlikely to be of clinical significance.</p><p>Antifungals:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itraconazole, a strong CYP3A4 inhibitor and a P‑gp inhibitor, at a dosage of 200&nbsp;mg/day increased the plasma concentrations of the active antipsychotic fraction by about 70%, at risperidone doses of 2 to 8&nbsp;mg/day.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, a strong CYP3A4 inhibitor and a P‑gp inhibitor, at a dosage of 200&nbsp;mg/day increased the plasma concentrations of risperidone and decreased the plasma concentrations of 9‑hydroxy‑risperidone.</p><p>Antipsychotics:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenothiazines may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.</p><p>Antivirals:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protease inhibitors: No formal study data are available; however, since ritonavir is a strong CYP3A4 inhibitor and a weak CYP2D6 inhibitor, ritonavir and ritonavir‑boosted protease inhibitors potentially raise concentrations of the risperidone active antipsychotic fraction.</p><p>Beta‑blockers:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some beta‑blockers may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.</p><p>Calcium channel blockers:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil, a moderate inhibitor of CYP3A4 and an inhibitor of P‑gp, increases the plasma concentration of risperidone and the active antipsychotic fraction.</p><p>Gastrointestinal drugs:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>H<sub>2</sub>‑receptor antagonists: Cimetidine and ranitidine, both weak inhibitors of CYP2D6 and CYP3A4, increased the bioavailability of risperidone, but only marginally that of the active antipsychotic fraction.</p><p>SSRIs and tricyclic antidepressants:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Fluoxetine, a strong CYP2D6 inhibitor, increases the plasma concentration of risperidone, but less so of the active antipsychotic fraction.</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Paroxetine, a strong CYP2D6 inhibitor, increases the plasma concentrations of risperidone, but, at dosages up to 20&nbsp;mg/day, less so of the active antipsychotic fraction. However, higher doses of paroxetine may elevate concentrations of the risperidone active antipsychotic fraction.</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Tricyclic antidepressants may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction. Amitriptyline does not affect the pharmacokinetics of risperidone or the active antipsychotic fraction.</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Sertraline, a weak inhibitor of CYP2D6, and fluvoxamine, a weak inhibitor of CYP3A4, at dosages up to 100&nbsp;mg/day are not associated with clinically significant changes in concentrations of the risperidone active antipsychotic fraction. However, doses higher than 100&nbsp;mg/day of sertraline or fluvoxamine may elevate concentrations of the risperidone active antipsychotic fraction.</p><p><u>&nbsp;</u></p><p><u>Effect of risperidone on the pharmacokinetics of other medicinal products</u></p><p>&nbsp;</p><p>Antiepileptics:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Risperidone does not show a clinically relevant effect on the pharmacokinetics of valproate or topiramate.</p><p>Antipsychotics:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Aripiprazole, a CYP2D6 and CYP3A4 substrate: Risperidone tablets or injections did not affect the pharmacokinetics of the sum of aripiprazole and its active metabolite, dehydroaripiprazole.</p><p>Digitalis glycosides:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Risperidone does not show a clinically relevant effect on the pharmacokinetics of digoxin.</p><p>Lithium:</p><p>●<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Risperidone does not show a clinically relevant effect on the pharmacokinetics of lithium.</p><p>&nbsp;</p><p><u>Concomitant use of risperidone with furosemide</u></p><p><u>&nbsp;</u></p><p>See section 4.4 regarding increased mortality in elderly patients with dementia concomitantly receiving furosemide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate data from the use of risperidone in pregnant women. Risperidone was not teratogenic in animal studies but other types of reproductive toxicity were seen (see section 5.3). The potential risk for humans is unknown.</p><p>Neonates exposed to antipsychotics (including RISPERDAL) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>RISPERDAL should not be used during pregnancy unless clearly necessary. If discontinuation during pregnancy is necessary, it should not be done abruptly.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>In animal studies, risperidone and 9‑hydroxy‑risperidone are excreted in the milk. It has been demonstrated that risperidone and 9‑hydroxy‑risperidone are also excreted in human breast milk in small quantities. There are no data available on adverse reactions in breast‑feeding infants. Therefore, the advantage of breast‑feeding should be weighed against the potential risks for the child.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>As with other drugs that antagonise dopamine D<sub>2</sub>&nbsp;receptors, RISPERDAL elevates prolactin level. Hyperprolactinaemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.</p><p>&nbsp;</p><p>There were no relevant effects observed in the non‑clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RISPERDAL can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8). Therefore, patients should be advised not to drive or operate machinery until their individual susceptibility is known.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse drug reactions (ADRs) (incidence &ge;&nbsp;10%) are: Parkinsonism, sedation/somnolence, headache, and insomnia.</p><p>The ADRs that appeared to be dose‑related included parkinsonism and akathisia.</p><p>&nbsp;</p><p>The following are all the ADRs that were reported in clinical trials and post‑marketing experience with risperidone by frequency category estimated from RISPERDAL clinical trials. The following terms and frequencies are applied: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:107%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="6" style="vertical-align:bottom"><p><strong>Adverse Drug Reaction</strong></p></td></tr><tr><td colspan="6" style="vertical-align:bottom"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:bottom"><p><strong>Very Common</strong></p></td><td style="vertical-align:bottom"><p><strong>Common</strong></p></td><td style="vertical-align:bottom"><p><strong>Uncommon</strong></p></td><td style="vertical-align:bottom"><p><strong>Rare</strong></p></td><td style="vertical-align:bottom"><p><strong>Very Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pneumonia, bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, ear infection, influenza</p></td><td style="vertical-align:top"><p>respiratory tract infection, cystitis, eye infection, tonsillitis, onychomycosis, cellulitis localised infection, viral infection, acarodermatitis</p></td><td style="vertical-align:top"><p>infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>neutropenia, white blood cell count decreased, thrombocytopenia, anaemia, haematocrit decreased, eosinophil count increased</p></td><td style="vertical-align:top"><p>agranulocytosis<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactic reaction<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperprolactinaemia<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>inappropriate antidiuretic hormone secretion, glucose urine present</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>weight increased, increased appetite, decreased appetite</p></td><td style="vertical-align:top"><p>diabetes mellitus<sup>b</sup>, hyperglycaemia, polydipsia, weight decreased, anorexia, blood cholesterol increased</p></td><td style="vertical-align:top"><p>water intoxication<sup>c</sup>, hypoglycaemia, hyperinsulinaemia<sup>c</sup>, blood triglycerides increased</p></td><td style="vertical-align:top"><p>diabetic ketoacidosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>insomnia<sup>d</sup></p></td><td style="vertical-align:top"><p>sleep disorder, agitation, depression, anxiety</p></td><td style="vertical-align:top"><p>mania, confusional state, libido decreased, nervousness, nightmare</p></td><td style="vertical-align:top"><p>catatonia, somnambulism, sleep-related eating disorder, blunted affect, anorgasmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>sedation/<br />somnolence, parkinsonism<sup>d</sup>, headache</p></td><td style="vertical-align:top"><p>akathisia<sup>d</sup>, dystonia<sup>d</sup>, dizziness, dyskinesia<sup>d</sup>, tremor</p></td><td style="vertical-align:top"><p>tardive dyskinesia, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, convulsion<sup>d</sup>, syncope, psychomotor hyperactivity, balance disorder, coordination abnormal, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top"><p>neuroleptic malignant syndrome, cerebrovascular disorder, diabetic coma, head titubation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vision blurred, conjunctivitis</p></td><td style="vertical-align:top"><p>photophobia, dry eye, lacrimation increased, ocular hyperaemia</p></td><td style="vertical-align:top"><p>glaucoma, eye movement disorder, eye rolling, eyelid margin crusting, floppy iris syndrome (intraoperative)<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vertigo, tinnitus, ear pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tachycardia</p></td><td style="vertical-align:top"><p>atrial fibrillation, atrioventricular block, conduction disorder, electrocardiogram QT prolonged, bradycardia, electrocardiogram abnormal, palpitations</p></td><td style="vertical-align:top"><p>sinus arrhythmia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>hypotension, orthostatic hypotension, flushing</p></td><td style="vertical-align:top"><p>pulmonary embolism, venous thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspnoea, pharyngolaryngeal pain, cough, epistaxis, nasal congestion</p></td><td style="vertical-align:top"><p>pneumonia aspiration, pulmonary congestion, respiratory tract congestion, rales, wheezing, dysphonia, respiratory disorder</p></td><td style="vertical-align:top"><p>sleep apnoea syndrome, hyperventilation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhoea, dyspepsia, dry mouth, toothache</p></td><td style="vertical-align:top"><p>faecal incontinence, faecaloma, gastroenteritis, dysphagia, flatulence</p></td><td style="vertical-align:top"><p>pancreatitis, intestinal obstruction, swollen tongue, cheilitis</p></td><td style="vertical-align:top"><p>ileus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rash, erythema</p></td><td style="vertical-align:top"><p>urticaria, pruritus, alopecia, hyperkeratosis, eczema, dry skin, skin discolouration, acne, seborrhoeic dermatitis, skin disorder, skin lesion</p></td><td style="vertical-align:top"><p>drug eruption, dandruff</p></td><td style="vertical-align:top"><p>angioedema</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome/toxic epidermal necrolysis<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>muscle spasms, musculoskeletal pain, back pain, arthralgia</p></td><td style="vertical-align:top"><p>blood creatine phosphokinase increased, posture abnormal, joint stiffness, joint swelling muscular weakness, neck pain</p></td><td style="vertical-align:top"><p>rhabdomyolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urinary incontinence</p></td><td style="vertical-align:top"><p>pollakiuria, urinary retention, dysuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium, and neonatal conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>drug withdrawal syndrome neonatal<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>erectile dysfunction, ejaculation disorder, amenorrhoea, menstrual disorder<sup>d</sup>, gynaecomastia, galactorrhoea, sexual dysfunction, breast pain, breast discomfort, vaginal discharge</p></td><td style="vertical-align:top"><p>priapism<sup>c</sup>, menstruation delayed, breast engorgement, breast enlargement, breast discharge</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>oedema<sup>d</sup>, pyrexia, chest pain, asthenia, fatigue, pain</p></td><td style="vertical-align:top"><p>face oedema, chills, body temperature increased, gait abnormal, thirst, chest discomfort, malaise, feeling abnormal, discomfort</p></td><td style="vertical-align:top"><p>hypothermia, body temperature decreased, peripheral coldness, drug withdrawal syndrome, induration<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>transaminases increased, gamma‑glutamyltransferase increased, hepatic enzyme increased</p></td><td style="vertical-align:top"><p>jaundice</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fall</p></td><td style="vertical-align:top"><p>procedural pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Hyperprolactinaemia can in some cases lead to gynaecomastia, menstrual disturbances, amenorrhoea, anovulation, galactorrhoea, fertility disorder, decreased libido, erectile dysfunction.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; In placebo‑controlled trials diabetes mellitus was reported in 0.18% in risperidone‑treated subjects compared to a rate of 0.11% in placebo group. Overall incidence from all clinical trials was 0.43% in all risperidone‑treated subjects.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; Not observed in RISPERDAL clinical studies but observed in post‑marketing environment with risperidone.</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp; </sup>Extrapyramidal disorder<sup> </sup>may occur: <strong>Parkinsonism</strong> (salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, and glabellar reflex abnormal, parkinsonian rest tremor), <strong>akathisia</strong> (akathisia, restlessness, hyperkinesia, and restless leg syndrome), tremor, <strong>dyskinesia </strong>(dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia. <strong>Dystonia </strong>includes dystonia, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus. It should be noted that a broader spectrum of symptoms are included, that do not necessarily have an extrapyramidal origin. <strong>Insomnia</strong> includes initial insomnia, middle insomnia. <strong>Convulsion</strong> includes grand mal convulsion. <strong>Menstrual disorder</strong> includes menstruation irregular, oligomenorrhoea. <strong>Oedema</strong> includes generalised oedema, oedema peripheral, pitting oedema.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Undesirable effects noted with paliperidone formulations</u></p><p>&nbsp;</p><p>Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another. In addition to the above adverse reactions, the following adverse reaction has been noted with the use of paliperidone products and can be expected to occur with RISPERDAL.</p><p>&nbsp;</p><p><strong>Cardiac disorders</strong></p><p>Postural orthostatic tachycardia syndrome</p><p>&nbsp;</p><p><em>Class effects</em></p><p>As with other antipsychotics, very rare cases of QT prolongation have been reported post‑marketing with risperidone. Other class‑related cardiac effects reported with antipsychotics which prolong QT interval include ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sudden death, cardiac arrest and Torsades de Pointes.</p><p>&nbsp;</p><p><strong>Venous thromboembolism</strong></p><p>Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotic drugs (frequency unknown).</p><p>&nbsp;</p><p><strong>Weight gain</strong></p><p>The proportions of RISPERDAL and placebo‑treated adult patients with schizophrenia meeting a weight gain criterion of &sup3;&nbsp;7% of body weight were compared in a pool of 6‑ to 8‑week, placebo‑controlled trials, revealing a statistically significantly greater incidence of weight gain for RISPERDAL (18%) compared to placebo (9%). In a pool of placebo‑controlled 3‑week studies in adult patients with acute mania, the incidence of weight increase of &sup3;&nbsp;7% at endpoint was comparable in the RISPERDAL (2.5%) and placebo (2.4%) groups, and was slightly higher in the active‑control group (3.5%).</p><p>&nbsp;</p><p>In a population of children and adolescents with conduct and other disruptive behaviour disorders, in long‑term studies, weight increased by a mean of 7.3&nbsp;kg after 12&nbsp;months of treatment. The expected weight gain for normal children between 5‑12&nbsp;years of age is 3 to 5&nbsp;kg per year. From 12‑16&nbsp;years of age, this magnitude of gaining 3 to 5&nbsp;kg per year is maintained for girls, while boys gain approximately 5&nbsp;kg per year.</p><p><strong>&nbsp;</strong></p><p><u>Additional information on special populations</u></p><p>&nbsp;</p><p>Adverse drug reactions that were reported with higher incidence in elderly patients with dementia or paediatric patients than in adult populations are described below:</p><p>&nbsp;</p><p><em>Elderly patients with dementia</em></p><p>Transient ischaemic attack and cerebrovascular accident were ADRs reported in clinical trials with a frequency of 1.4% and 1.5%, respectively, in elderly patients with dementia. In addition, the following ADRs were reported with a frequency &sup3;&nbsp;5% in elderly patients with dementia and with at least twice the frequency seen in other adult populations: urinary tract infection, peripheral oedema, lethargy, and cough.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In general, type of adverse reactions in children is expected to be similar to those observed in adults.</p><p>The following ADRs were reported with a frequency &sup3;&nbsp;5% in paediatric patients (5 to 17&nbsp;years) and with at least twice the frequency seen in clinical trials in adults: somnolence/sedation, fatigue, headache, increased appetite, vomiting, upper respiratory tract infection, nasal congestion, abdominal pain, dizziness, cough, pyrexia, tremor, diarrhoea, and enuresis.</p><p>The effect of long‑term risperidone treatment on sexual maturation and height has not been adequately studied (see section 4.4, subsection &ldquo;Paediatric population&rdquo;).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Bundesinstitut f&uuml;r Arzneimittel und Medizinprodukte, Abt. Pharmakovigilanz, Kurt-Georg-Kiesinger Allee&nbsp;3, D‑53175 Bonn, Website: http://www.bfarm.de.</p><p>&nbsp;</p><p><strong>To Report any side effect (s):</strong></p><p><strong>&nbsp;&bull; Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><ul><li><ul><li>Fax: +966-11-205-7662</li><li><u>SFDA Call Center: 19999</u></li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&bull;<strong> Other GCC States:&nbsp; </strong></p><p>&minus;<em> Please contact the relevant competent authority. </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><em>Symptoms</em></p><p>In general, reported signs and symptoms have been those resulting from an exaggeration of the known pharmacological effects of risperidone. These include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. In overdose, QT prolongation and convulsions have been reported. Torsade de Pointes has been reported in association with combined overdose of RISPERDAL and paroxetine.</p><p>&nbsp;</p><p>In case of acute overdose, the possibility of multiple drug involvement should be considered.</p><p>&nbsp;</p><p><em>Treatment</em></p><p>Establish and maintain a clear airway and ensure adequate oxygenation and ventilation. Administration of activated charcoal together with a laxative should be considered only when drug intake was less than one hour before. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.</p><p>&nbsp;</p><p>There is no specific antidote to RISPERDAL. Therefore, appropriate supportive measures should be instituted. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. In case of severe extrapyramidal symptoms, an anticholinergic medicinal product should be administered. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antipsychotics, ATC code: N05AX08.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Risperidone is a selective monoaminergic antagonist with unique properties. It has a high affinity for serotoninergic 5‑HT<sub>2</sub> and dopaminergic D<sub>2</sub>&nbsp;receptors. Risperidone binds also to alpha<sub>1</sub>‑adrenergic receptors, and, with lower affinity, to H<sub>1</sub>‑histaminergic and alpha<sub>2</sub>‑adrenergic receptors. Risperidone has no affinity for cholinergic receptors. Although risperidone is a potent D<sub>2</sub>&nbsp;antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.</p><p><em>&nbsp;</em></p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p><em><u>Clinical efficacy</u></em></p><p><em>&nbsp;</em></p><p><em>Schizophrenia</em></p><p>The efficacy of risperidone in the short‑term treatment of schizophrenia was established in four studies, 4 to 8&nbsp;weeks in duration, which enrolled over 2,500&nbsp;patients who met DSM‑IV criteria for schizophrenia. In a 6‑week, placebo‑controlled trial involving titration of risperidone in doses up to 10&nbsp;mg/day administered twice daily, risperidone was superior to placebo on the Brief Psychiatric Rating Scale (BPRS) total score. In an 8‑week, placebo‑controlled trial involving four fixed doses of risperidone (2, 6, 10, and 16&nbsp;mg/day, administered twice daily), all four risperidone groups were superior to placebo on the Positive and Negative Syndrome Scale (PANSS) total score. In an 8‑week, dose comparison trial involving five fixed doses of risperidone (1, 4, 8, 12, and 16&nbsp;mg/day administered twice daily), the 4, 8, and 16&nbsp;mg/day risperidone dose groups were superior to the 1&nbsp;mg risperidone dose group on PANSS total score. In a 4‑week, placebo‑controlled dose comparison trial involving two fixed doses of risperidone (4 and 8&nbsp;mg/day administered once daily), both risperidone dose groups were superior to placebo on several PANSS measures, including total PANSS and a response measure (&gt;&nbsp;20% reduction in PANSS total score). In a longer‑term trial, adult outpatients predominantly meeting DSM‑IV criteria for schizophrenia and who had been clinically stable for at least 4&nbsp;weeks on an antipsychotic medicinal product were randomised to risperidone 2 to 8&nbsp;mg/day or to haloperidol for 1 to 2&nbsp;years of observation for relapse. Patients receiving risperidone experienced a significantly longer time to relapse over this time period compared to those receiving haloperidol.</p><p>&nbsp;</p><p><em>Manic episodes in bipolar disorder</em></p><p>The efficacy of risperidone monotherapy in the acute treatment of manic episodes associated with bipolar&nbsp;I disorder was demonstrated in three double‑blind, placebo‑controlled monotherapy studies in approximately 820&nbsp;patients who had bipolar&nbsp;I disorder, based on DSM‑IV criteria. In the three studies, risperidone 1 to 6&nbsp;mg/day (starting dose 3&nbsp;mg in two studies and 2&nbsp;mg in one study) was shown to be significantly superior to placebo on the pre‑specified primary endpoint, i.e., the change from baseline in total Young Mania Rating Scale (YMRS) score at week&nbsp;3. Secondary efficacy outcomes were generally consistent with the primary outcome. The percentage of patients with a decrease of &sup3;&nbsp;50% in total YMRS score from baseline to the 3‑week endpoint was significantly higher for risperidone than for placebo. One of the three studies included a haloperidol arm and a 9‑week double‑blind maintenance phase. Efficacy was maintained throughout the 9‑week maintenance treatment period. Change from baseline in total YMRS showed continued improvement and was comparable between risperidone and haloperidol at week&nbsp;12.</p><p>&nbsp;</p><p>The efficacy of risperidone in addition to mood stabilisers in the treatment of acute mania was demonstrated in one of two 3‑week double‑blind studies in approximately 300&nbsp;patients who met the DSM‑IV criteria for bipolar&nbsp;I disorder. In one 3‑week study, risperidone 1 to 6&nbsp;mg/day starting at 2&nbsp;mg/day in addition to lithium or valproate was superior to lithium or valproate alone on the pre‑specified primary endpoint, i.e., the change from baseline in YMRS total score at week&nbsp;3. In a second 3‑week study, risperidone 1 to 6&nbsp;mg/day starting at 2&nbsp;mg/day, combined with lithium, valproate, or carbamazepine was not superior to lithium, valproate, or carbamazepine alone in the reduction of YMRS total score. A possible explanation for the failure of this study was induction of risperidone and 9‑hydroxy‑risperidone clearance by carbamazepine, leading to subtherapeutic levels of risperidone and 9‑hydroxy‑risperidone. When the carbamazepine group was excluded in a post‑hoc analysis, risperidone combined with lithium or valproate was superior to lithium or valproate alone in the reduction of YMRS total score.</p><p>&nbsp;</p><p><em>Persistent aggression in dementia</em></p><p>The efficacy of risperidone in the treatment of Behavioural and Psychological Symptoms of Dementia (BPSD), which includes behavioural disturbances, such as aggressiveness, agitation, psychosis, activity, and affective disturbances was demonstrated in three double‑blind, placebo‑controlled studies in 1,150&nbsp;elderly patients with moderate to severe dementia. One study included fixed risperidone doses of 0.5, 1, and 2&nbsp;mg/day. Two flexible‑dose studies included risperidone dose groups in the range of 0.5 to 4&nbsp;mg/day and 0.5 to 2&nbsp;mg/day, respectively. Risperidone showed statistically significant and clinically important effectiveness in treating aggression and less consistently in treating agitation and psychosis in elderly dementia patients (as measured by the Behavioural Pathology in Alzheimer&rsquo;s Disease Rating Scale [BEHAVE‑AD] and the Cohen‑Mansfield Agitation Inventory [CMAI]). The treatment effect of risperidone was independent of Mini‑Mental State Examination (MMSE) score (and consequently of the severity of dementia); of sedative properties of risperidone; of the presence or absence of psychosis; and of the type of dementia, Alzheimer&rsquo;s, vascular, or mixed (see also section 4.4).</p><p><em>&nbsp;</em></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p><em>Conduct disorder</em></p><p>The efficacy of risperidone in the short‑term treatment of disruptive behaviours was demonstrated in two double‑blind placebo‑controlled studies in approximately 240&nbsp;patients 5 to 12&nbsp;years of age with a DSM‑IV diagnosis of disruptive behaviour disorders (DBD) and borderline intellectual functioning or mild or moderate mental retardation/learning disorder. In the two studies, risperidone 0.02 to 0.06&nbsp;mg/kg/day was significantly superior to placebo on the pre‑specified primary endpoint, i.e., the change from baseline in the Conduct Problem subscale of the Nisonger‑Child Behaviour Rating Form (N‑CBRF) at week&nbsp;6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RISPERDAL oral solution is bioequivalent to RISPERDAL film‑coated tablets.</p><p>Risperidone is metabolised to 9‑hydroxy‑risperidone, which has a similar pharmacological activity to risperidone (see <em>Biotransformation and Elimination</em>).</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Risperidone is completely absorbed after oral administration, reaching peak plasma concentrations within 1 to 2&nbsp;hours. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) compared with a solution. The absorption is not affected by food and thus risperidone can be given with or without meals. Steady‑state of risperidone is reached within 1&nbsp;day in most patients. Steady‑state of 9‑hydroxy‑risperidone is reached within 4‑5&nbsp;days of dosing.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Risperidone is rapidly distributed. The volume of distribution is 1‑2&nbsp;l/kg. In plasma, risperidone is bound to albumin and alpha<sub>1</sub>‑acid glycoprotein. The plasma protein binding of risperidone is 90%, that of 9‑hydroxy‑risperidone is 77%.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>Risperidone is metabolised by CYP2D6 to 9‑hydroxy‑risperidone, which has a similar pharmacological activity as risperidone. Risperidone plus 9‑hydroxy‑risperidone form the active antipsychotic fraction. CYP2D6 is subject to genetic polymorphism. Extensive CYP2D6 metabolisers convert risperidone rapidly into 9‑hydroxy‑risperidone, whereas poor CYP2D6 metabolisers convert it much more slowly. Although extensive metabolisers have lower risperidone and higher 9‑hydroxy‑risperidone concentrations than poor metabolisers, the pharmacokinetics of risperidone and 9‑hydroxy‑risperidone combined (i.e., the active antipsychotic fraction), after single and multiple doses, are similar in extensive and poor metabolisers of CYP2D6.</p><p>&nbsp;</p><p>Another metabolic pathway of risperidone is N‑dealkylation. <em>In vitro</em> studies in human liver microsomes showed that risperidone at clinically relevant concentration does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. One week after administration, 70% of the dose is excreted in the urine and 14% in the faeces. In urine, risperidone plus 9‑hydroxy‑risperidone represent 35‑45% of the dose. The remainder is inactive metabolites. After oral administration to psychotic patients, risperidone is eliminated with a half‑life of about 3&nbsp;hours. The elimination half‑life of 9‑hydroxy‑risperidone and of the active antipsychotic fraction is 24&nbsp;hours.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>Risperidone plasma concentrations are dose‑proportional within the therapeutic dose‑range.</p><p>&nbsp;</p><p><u>Elderly, hepatic and renal impairment</u></p><p>&nbsp;</p><p>A single‑dose PK‑study with oral risperidone showed on average a 43% higher active antipsychotic fraction plasma concentrations, a 38% longer half‑life and a reduced clearance of the active antipsychotic fraction by 30% in the elderly.</p><p>&nbsp;</p><p>In adults with moderate renal disease the clearance of the active moiety was ~48% of the clearance in young healthy adults. In adults with severe renal disease the clearance of the active moiety was ~31% of the clearance in young healthy adults. The half‑life of the active moiety was 16.7&nbsp;h in young adults, 24.9&nbsp;h in adults with moderate renal disease (or ~1.5&nbsp;times as long as in young adults), and 28.8&nbsp;h in those with severe renal disease (or ~1.7&nbsp;times as long as in young adults). Risperidone plasma concentrations were normal in patients with liver insufficiency, but the mean free fraction of risperidone in plasma was increased by 37.1%.</p><p>&nbsp;</p><p>The oral clearance and the elimination half‑life of risperidone and of the active moiety in adults with moderate and severe liver impairment were not significantly different from those parameters in young healthy adults.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The pharmacokinetics of risperidone, 9‑hydroxy‑risperidone and the active antipsychotic fraction in children are similar to those in adults.</p><p>&nbsp;</p><p><u>Gender, race and smoking habits</u></p><p><u>&nbsp;</u></p><p>A population pharmacokinetic analysis revealed no apparent effect of gender, race or smoking habits on the pharmacokinetics of risperidone or the active antipsychotic fraction.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In (sub)chronic toxicity studies, in which dosing was started in sexually immature rats and dogs, dose‑dependent effects were present in male and female genital tract and mammary gland. These effects were related to the increased serum prolactin levels, resulting from the dopamine D<sub>2</sub>&nbsp;receptor blocking activity of risperidone. In addition, tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Risperidone was not teratogenic in rat and rabbit. In rat reproduction studies with risperidone, adverse effects were seen on mating behaviour of the parents, and on the birth weight and survival of the offspring. In rats, intrauterine exposure to risperidone was associated with cognitive deficits in adulthood. Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring. In a toxicity study in juvenile rats, increased pup mortality and a delay in physical development was observed. In a 40‑week study with juvenile dogs, sexual maturation was delayed. Based on AUC, long bone growth was not affected in dogs at 3.6‑times the maximum human exposure in adolescents (1.5&nbsp;mg/day); while effects on long bones and sexual maturation were observed at 15&nbsp;times the maximum human exposure in adolescents.</p><p>&nbsp;</p><p>Risperidone was not genotoxic in a battery of tests. In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. These tumours can be related to prolonged dopamine D<sub>2</sub>&nbsp;antagonism and hyperprolactinaemia. The relevance of these tumour findings in rodents in terms of human risk is unknown. <em>In vitro</em> and <em>in vivo</em>, animal models show that at high doses risperidone may cause QT interval prolongation, which has been associated with a theoretically increased risk of Torsade de Pointes in patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong></p><p>&nbsp;</p><p>Tartaric acid (E334) (Ph.&nbsp;Eur.)</p><p>Benzoic acid (E210)</p><p>Sodium hydroxide</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RISPERDAL oral solution 1&nbsp;mg/ml is incompatible with most types of tea including black tea.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Shelf life after first opening: 3 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Do not refrigerate or freeze.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Original packs:</p><p>Amber glass bottle with a plastic (polypropylene) child‑resistant and tamper‑evident cap.</p><p>RISPERDAL oral solution is presented in bottle sizes of 30&nbsp;ml, 60&nbsp;ml, 100&nbsp;ml and 120&nbsp;ml with a dosing pipette (certificated medical device).</p><p>Clinic pack (bundled):</p><p>500&nbsp;ml (5&nbsp;x&nbsp;100&nbsp;ml) solution.</p><p>&nbsp;</p><p>The pipette supplied with the bottle size of 30&nbsp;ml, 60&nbsp;ml and 100&nbsp;ml is graduated in milligrams and millilitres with a minimum volume of 0.25&nbsp;ml and a maximum volume of 3&nbsp;ml. Graduation marks in 0.25&nbsp;ml (equals 0.25&nbsp;mg oral solution) increments up to 3&nbsp;ml (equals 3&nbsp;mg oral solution) are printed on this pipette.</p><p>&nbsp;</p><p>The pipette supplied with the bottle size of 120&nbsp;ml is graduated in milligrams and millilitres with a minimum volume of 0.25&nbsp;ml and a maximum volume of 4&nbsp;ml. Graduation marks in 0.25&nbsp;ml (equals 0.25&nbsp;mg oral solution) increments up to 4&nbsp;ml (equals 4&nbsp;mg oral solution) are printed on this pipette.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
JANSSEN-CILAG GmbH
Johnson & Johnson Platz 1
41470 Neuss
Tel.: 02137 / 955-955
www.janssen.com/germany


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19-August-2022

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>